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Abstract
Recurrent aphthous ulcer (RAU) is an ulcerative disease of the oral mucosa
characterised by the appearance of ulcerations in the oral mucosa accompanied
by an erythematous halo area surrounding the ulcer and showing signs of acute
inflammation.
While RAU affects approximately 20% of the population globally, its
pathogenesis remains poorly understood. Furthermore, most studies concentrate
on treatment while few address the pathogenesis of the disease.
This project aimed to determine the mechanisms of oral epithelial cell death in
RAU, the role of these cells in disease pathogenesis in terms of toll-like receptor
(TLR) expression, and the ability of the these cells to produce chemokines, pro-
inflammatory cytokines, and antimicrobial peptides. Together these may first
aggravate and, then, down-regulate the inflammation and initiate the healing
process.
For this purpose, we collected 13 aphthae and 11 healthy control biopsies for
immunohistochemical staining, immunofluorescence staining, and quantitative
PCR. For functional studies, we cultured primary oral keratinocytes and oral
squamous cell carcinoma cell-line SCC-25 and tested their responses to different
stimuli.
Our results highlight the importance of oral epithelial cells in RAU;
interestingly, oral epithelial cells in RAU tested positive for apoptosis markers
caspase-3, especially at the superficial and spinous layer, and TUNEL, but
negative in controls. We also found that TLRs are primarily present in the basal
and suprabasal layers of control epithelium, but their expression extends to the
superficial layer in RAU epithelium. Additionally, we found significally higher
expressions of tumour necrosis factor-α (TNF-α), interleukin-8 (IL-8), IL-17C,
and beta defensin 2 (BD-2) in RAU oral epithelium compared with control
epithelium.
xii
Functional studies on cultured primary oral keratinocytes and SCC-25 supported
our results from RAU biopsies since these cells responded to damage-associated
molecule patterns (DAMPs), such as self-DNA and pro-inflammatory cytokines
including IL-17C, TNF-α, and interferon gamma (IFN-γ), through a significant
increase in the expression of selected molecules including TLR2, TNF-α, and
BD-2.
Based on our findings, RAU may begin with a strong initiating factor activating
a self-amplificatory cycle. This cycle is characterised by the induction of
epithelial cells apoptosis at the superficial layer down to the basal layer, a
change in the pattern of TLR distribution, the up-regulation of several
chemokines and pro-inflammatory cytokines, and, finally, the secretion of
antimicrobial peptides initating the healing process. As a result of the lack of
adaptive immunity in RAU, the cycle recurs when the mucosa is subjected to an
initiating factor of the same sequence.
11. Introduction
Oral ulcerative diseases represent a group of mucosal disorders which affect oral
mucosa; the most common type of oral ulcerations are recurrent aphthous ulcers
(RAUs) or (canker sores). The word aphthous (meaning ‘ulcer’ in Greek) was first
used by Hippocrates (460–370 BC) to describe ulcerations in the oral mucosa.
Canker sores, which is Latin in origin, was also used at that time.
Despite centuries of knowledge about RAUs, which currently affect approximately
20%  of  the  population,  their  origin  remains  unknown.  Even  after  thousands  of
studies beginning with an article published by Mikulicz and Kümmel in 1898, the
exact reason for the appearance of RAU remains elusive. Based on these studies,
however, scholars suggested several aetiological factors that play a role in RAU
onset. Some scholars argued that RAUs serve as a sign of other systemic diseases
such as Behçet's disease.
RAU represents an acute inflammation usually affecting non-keratinised oral
mucosa, such as the tongue, labial, and buccal mucosa, RAU can also affect
keratinized oral mucosa such as palate and attached gingiva although such
instances are uncommon.
A RAU lesion is a self-healing ulceration; the ulcer appears within a few hours and
persists for 5 to 10 days in a minor form, during which time the inflammation
subsides and the ulcer heals. During the ulcer episode, the patient suffers from
severe pain and difficulties eating, speaking, and swallowing especially if the ulcer
is located on the tongue.
A RAU lesion is characterised by the complete loss of the epithelium, which
appears clinically as white or gray in colour and is surrounded by a red
erythematous halo area, possibly indicating the severity of the inflammation in the
area. As a result of the acute inflammation, a RAU lesion is highly infiltrated by
several types of inflammatory cells, such as neutrophils, lymphocytes,
macrophages, and others, which may at first fight microbes that have easy access to
2the oral mucosa through the unprotected ulcer area. Second, the inflammation may
increase, indicating the first step in healing.
Since the initial cause of disease remains unknown, the reasons behind the quite
rapid  ability  of  the  oral  mucosa  to  repair  after  an  acute  inflammation  remain
unclear.
Because immune cells are the primary producers of cytokines and chemokines,
most studies on RAU addressed the role of immune cells in pathogenesis. Few
studies addressed the role of oral epithelial cells in RAUs and the possible causes
for epithelium loss.
Here, we suggest that oral epithelial cells play an active role in RAUs through the
release of a cocktail of alarmins, chemokines, cytokines, and antimicrobial peptides
which work together to up-regulate the inflammation and initiate the healing
process.
32. Review of the literature
2.1. Definition of RAU
RAU is an acute inflammatory ulcerative disease that affects the oral mucosa
characterised by recurrent episodes of oral ulcerations accompanied by severe pain
affecting the everyday lives of patients (Scully and Porter, 2008).
2.2. Classification of RAU
Three  forms  of  RAUs  exist,  depending  on  the  size  of  the  ulcer,  the  number  of
ulcers per episode, the duration of healing, and the ability to heal without scar
formation. The three forms are as follows.
Minor RAU represents  the  most  common  form  ,  comprising  80%  of  all  RAU
cases. Characteristics of minor RAU include their small size (less than 10 mm) and
one or multiple (up to five) ulcers primarily affecting non-keratinised oral mucosa
or the palate and attached gingiva in rare cases. The ulcer is painful and takes seven
to  ten  days  to  heal  spontaneously  without  scars  forming.  This  type  of  ulcer
normally affects children and young people (Figure 1).
Major RAU represents the second type, regarded as the severest type of RAU.
These types of ulcers normally appear larger than 10 mm and penetrate deeper than
minor  RAU,  leading  to  severe  pain  and  a  longer  healing  period  of  six  weeks  or
more. Scar formation normally accompanies healing. Major RAUs usually occur
after puberty.
Herpetiform RAUs are characterised by multiple (up to 100 or more), small (2 to
3 mm) ulcers sometimes fused to form a large ulcer. The herpetiform RAU took its
name from the herpes simplex virus (HSV) because of its resemblance to oral
symptoms.  Herpetiform  RAUs  take  seven  to  ten  days  to  heal  without  scar
formation.
4Figure 1. Minor RAU of the labial mucosa (Scully and Felix, 2005).
2.3. Epidemiology of RAU
While no population-based studies on the prevalence and incidence of RAU exist,
reports from various countries showed that their prevalence varies geographically.
RAU seems uncommon among Bedouin Arabs (Fahmy, 1976) and more frequent
in Western European countries and in North America (Embil et al., 1975). Others
found that RAU affects 5% to 66% of the the population (Fahmy, 1976; Miller et
al., 1980), with a global estimated prevalence of 20% (Axell and Henricsson, 1985;
SIRCUS et al., 1957). The prevalence of RAU in selected countries is presented in
table 1. With regards to gender, some studies found that RAU affects more females
than males (Pongissawaranun and Laohapand, 1991; SHIP et al., 1961),
particularly among children (Field et al., 1992), while other studies found no
gender difference (Miller et al., 1980). Saraceno et al reported recently that RAU
affects 43% of Italians ageing between 2 and 17 years (Saraceno et al., 2015).
RAU affects students and individuals from a higher socioeconomic class (Crivelli
et al., 1988; SHIP et al., 1961; Ship, 1966). The chance of one’s offspring
acquiring RAU increases by 63.3% to 90% if both parents experience RAU.
Additionally, children with a family history suffer from RAU at an earlier age and
5experience stronger RAU episodes (Miller and Ship, 1977; Miller et al., 1980;
Ship, 1965).
Table 1. Prevalence of recurrent aphthous ulcers in selected countries.
RAU prevalence (%) Population studies References
Clinical
examination
Patient’s history Country Number of
participants
Age of
participants
1.2 USA 7,785 17-39 (Rivera-Hidalgo et al.,
2004)
1.03 USA 33,994 <1-≥60 (Chattopadhyay and
Chatterjee, 2007)
1.2 Turkey 765 5-95 (Mumcu et al., 2005)
1.4 18.3 Germany 655 35-44 (Reichart, 2000)
9.7 Slovenia 555 15-65 (Kovac-Kovacic and
Skaleric, 2000)
78.1 Jordan 684 13-68 (Safadi, 2009)
2.0 27.3 Poland 814 14-18 (Gorska, 1997)
Modified from Slebioda et al. (Slebioda et al., 2014).
2.4. Predisposing factors for RAU
Table 2 summarises the factors predisposing individuals to RAU (page 14).
Age and sex
RAU episodes begin at a young age, whereby 40% of children 15 years old or
younger suffer from RAU, with the first ulcer appearing before the age of 5 years
(Miller et al., 1980). A minor RAU normally appears in the second decade of life,
while a hepitiform RAU appears in the third decade of life (Scully and Porter,
1989). Some studies found that females (both adults and children) are more
predisposed to RAU than males, while others found no gender difference (Miller et
al., 1980; Pongissawaranun and Laohapand, 1991; SHIP et al., 1961). Axéll and
Henricsson (1985) found that RAU episodes decrease in both males and females
with an increasing age among a Swedish population (Axell and Henricsson, 1985),
while Sircus et al. found that such a decrease occured only in males in a Scottish
population (SIRCUS et al., 1957).
6Heredity
When both parents experience RAU, children have a 63.% to 90% chance of
experiening RAU compared to 20% of children with no family history of RAU
(Ship, 1972). Children with a family history of RAU suffer from RAU episodes
earlier than others, and the episodes are normally more severe in these children
(Miller and Ship, 1977; Miller et al., 1980; Ship, 1965). Several studies found an
association between RAU and genetically specific human leukocytes antigen
(HLA) subtypes among different ethnic groups.
RAU incidence was associated with an increase in HLA2 (Challacombe et al.,
1977), B12 (Lehner et al., 1982; Malmstrom et al., 1983), HLA-B51 in Korean and
Jewish populations, Cw7 in Jewish populations (Chang et al., 2001; Shohat-
Zabarski et al., 1992), DR2 (Lehner et al., 1982), DR4 in Turkish populations
(Ozbakir et al., 1987), DR5, A28 in Greek populations (Albanidou-Farmaki et al.,
1988), DRw9 in Chinese populations (Sun et al., 1991), DR7, and MT3 in Sicilians
(Gallina et al., 1985; Gallina et al., 1985).
Other studies found an inverse relationship between some genes and RAU, such as
HLA-B5 in Sicilians (Gallina et al., 1985) and DR4 in Greeks (Albanidou-Farmaki
et al., 1988).
Furthermore, a single nucleotide polymorphism for a high tumor necrosis factor
(TNF)-α and interleukin (IL)-β production is associated with a high prevalence of
RAU in a Brazilian population (Guimaraes et al., 2006; Guimaraes et al., 2007).
Genetic studies found some inconsistencies which may result from differences in
the ethnic groups studied.
7Hormonal disturbance
While researchers have studied the relationship between a hormonal disturbance
and RAU intensively, no clear results were found. McCartan and Sullivan
completed one of the most important reviews in this field (McCartan and Sullivan,
1992) covering all articles published from 1942 to 1991. In this review, the authors
concluded that no clear relationship between RAU and the premenstrual period,
menopause, or pregnancy exists. They suggested that this may result from an
improper reseach design or too few study participants. Yet, some conflicting results
from the review exist, such as the remission of RAU during pregnancy (Bishop et
al., 1967; SIRCUS et al., 1957), no men over 50 years old develop RAU, and only
10% of women experienced their first episode of RAU between the ages of 50 and
59,  which  may represent  a  symptom for  another  disease  entirely  (SIRCUS et  al.,
1957). In addition, 30% of 40 young women selected for one study experienced
RAU a few days prior to menstruation (Balan et al., 2012).
Haematological disturbance
Haematological disturbances may represent an important predisposing factor for
RAU. The overall frequency of hematinic deficiency was significantly higher in
RAU inidividuals than in healthy controls (Compilato et al., 2010; Lopez-Jornet et
al., 2014). While some studies found that serum vitamin B12, serum ferritin,
haematocrit, and red blood cell (RBC) folate were significantly lower in RAU
individuals compared with healthy controls (Khan et al., 2013; Piskin et al., 2002).
Contradictory to that, Thongprasom and coworkers showed that only RBC folate
was significantly lower in RAU individuals with no significant difference found in
serum vitamin B12, hemoglobin, haematocrit, and mean corpuscular hemoglobin
concentrations (Thongprasom et al., 2002). Additionally, the daily intake of
vitamin B12 and folate in RAU patients was significantly lower than that in healthy
individuals (Kozlak et al., 2010). Replacement therapy using vitamins served as an
8effective method to treat RAU, whereby vitamins B1, B2, and B6 and folic acid
significantly decreased RAU episodes and led to complete remission in some cases
(Nolan et al., 1991; Volkov et al., 2009). RAU patients suffering from vitamin B12
and folic acid deficiencies responded to replacement therapy better than those with
an iron deficiency (Wray et al., 1975).
Even with such promising results, vitamin deficiencies cannot be considered the
main aetiological factor for RAU. In contrast to the above studies, Lalla et al. found
no  beneficiary  effect  from  multivitamin  therapy  on  the  number  and  duration  of
RAU episodes (Lalla et al., 2012). Such results can give an indication that vitamin
replacement therapy might be helpful for those RAU patients suffering from
vitamin deficiency.
Stress and psychological profiles
Stress has always been regarded as one of the primary predisposing factors for
RAU, particularly among laypersons (Zadik et al., 2012).
RAU patients exhibit higher levels of psychological stress and anxiety, and appear
angrier than healthy individuals (Albanidou-Farmaki et al., 2008; Al-Omiri et al.,
2012; Gallo Cde et al., 2009). A study by Huling et al. concluded that stressful
events may be associated with the onset of RAU, but not with the duration of an
ulcer (Huling et al., 2012).
In contrast to the above studies, other studies found no differences in the levels of
depression and stress between the acute and remission phases of RAU, the periods
during  which  an  ulcer  was  present  and  absent,  or  between  RAU  patients  and
healthy controls (Huling et al., 2012; Pedersen, 1989).
Decreasing  levels  of  stress  positively  affected  RAU  patients.  Among  12  RAU
patients, symptoms improved after using Flupentixol® and Melitracen® prescribed
as antidepressants (Yaacob and Ab Hamid, 1985). The frequency of RAU episodes
9significantly decreased after subjecting patients to relaxation and imagery training
(Andrews and Hall, 1990).
No clear relationship between RAU and stress has been established and no clear
explanation about the role of stress in the onsest of RAU has been found; yet, some
scholars suggest that stress may change the immune system of the oral mucosa.
Such contradictory results leave the door open regarding the role of stress in RAU.
Smoking and the role of nicotine in RAU
Smoking is regarded as the leading cause of several diseases, including cancer,
cardiovascular disease and lung disease among others. Despite its harmful effects
on human health, nicotine carries some beneficial effects for RAU patients.
The protective role of smoking against RAU was first reported in 1960 by
Bookman, who documented the complete remission of RAU in four patients after
the resumption of smoking (Bookman, 1960). Four years later, Drosey reported
similar results in three patients (DORSEY, 1964).
A significant negative correlation was found between RAU and smoking in three
different studies among three different populations (Axell and Henricsson, 1985;
Rivera-Hidalgo et al., 2004; Tuzun et al., 2000). In contrast to these studies, among
1000 students at the University of Jordan, no significant difference in the annual
prevalence of RAU was found between smoking and non-smoking students. In the
same study, students classified as long-term heavy smokers reported significantly
fewer RAU episodes than those identified as moderate smokers for a shorter time
(Sawair, 2010).
Individuals who ceased smoking experienced a significant increase in RAU
especially after the first week of smoking cessation (Marakoglu et al., 2007; Ussher
et al., 2003).
To confirm the protective role of nicotine in RAU, nicotine replacement (nicotine
lozenges) were successfully used to treat RAU (Hill et al., 2010).
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This protective effect of smoking in general and specifically nicotine was
associated with two main factors. First, the increase in keratin production from oral
epithelial cells resulted nicotine stimulation; second, the inhibition of the
production of pro-inflammatory cytokines, such as TNF-α, IL-1, and IL-6, and the
increase in the production of anti-inflammatory cytokine IL-10 (Subramanyam,
2011) were associated with nicotine.
Oxidant and antioxidant status in RAU
The total oxidant/antioxidant ratio and total oxidative stress may play important
roles in the pathogenesis of RAU.
The total antioxidant status of sera significantly decreases in RAU patients
compared with healthy controls, a finding that contradicts the oxidant status and
total oxidative stress (Akoglu et al., 2013; Bilgili et al., 2013). A similar pattern
could not be found in the saliva, since no difference was found in the total
antioxidant capacity, total oxidant status, and the oxidative stress level between
RAU and healthy control subjects (Caglayan et al., 2008).
A significant down-regulation in the activity of antioxidant enzymes, such as
catalase, glutathione peroxidase, and paraoxonase 1 arylesterase, was found in the
plasma, serum, and erythrocytes of RAU patients compared with healthy controls
(Arikan et al., 2009; Bilgili et al., 2013; Cimen et al., 2003; Karincaoglu et al.,
2005; Ozturk et al., 2013).
Malondialdehyde, the end product of lipid peroxidation and an indicator of
oxidative stress, significantly increases in the plasma, serum, and saliva of RAU
patients compared with healthy controls (Arikan et al., 2009; Cimen et al., 2003;
Saral et al., 2005).
Karincaoglu et al. studied oxidative stress by evaluating the antioxidant enzymes in
the  plasma  and  saliva  of  30  RAU  patients  compared  with  30  healthy  controls.
Interestingly, the authors found that the levels of catalase and superoxide dismutase
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were significantly lower, while the level of glutathione peroxidase was higher in
the plasma of RAU patients compared with healthy controls. The exact opposite
was found in the saliva of the same patients and controls from that same study. The
authors suggested that this high level of antioxidant enzymes in the saliva may play
an important role in protecting the ulcer area. They also argued that the incongruity
in the level of antioxidant enzymes between the plasma and saliva may relate to the
body’s ability to mobilise antioxidant enzymes to the site where they are needed
(Karincaoglu et al., 2005).
2.5. Aetiological factors of RAU
Table 2 provides a summary of the aetiological factors associated with RAU (page
14).
Irritating agents
Sodium lauryl sulphate (SLS) is the most common irritant to the oral mucosa given
its frequent use in dentifrices. SLS significantly increased the number of RAU
episodes, the duration of an ulcer, and the mean pain score (Chahine et al., 1997;
Herlofson  and  Barkvoll,  1994;  Shim et  al.,  2012).  The  effects  of  SLS may result
from a direct irritation to the oral epithelium (van der Valk et al., 1984; Willis et
al., 1989), resulting in sloughing, ulceration, and finally inflammation (Herlofson
and Barkvoll, 1993; Rubright et al., 1978; Searls and Berg, 1986); a reduction in
the protective layer functioning (Siegel and Gordon, 1985; Siegel and Gordon,
1985); a reduction in the keratinisation index (Jacoby et al., 1975); and the
denaturation of proteins due to the high affinity of SLS to proteins (Tzutzumi et al.,
1982). Interstingly, Neppelberg et al. (2007) showed that the effects of SLS on
human oral keratinocytes depend on the SLS concentration. Thus, a low
concentration of SLS (0.015%) led to an increase in the epithelium thickness, the
proliferation of epithelial cells, and the expression of E-cadherin, and a very low
number of apoptotic cell deaths. By contrast, a high concentration of SLS (>0.15%)
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led to a decrease in the epithelium thickness, the proliferation of epithelial cells, the
expression of E-cadherin, the detachement of cells from each other, and an increase
in epithelial cell deaths (Neppelberg et al., 2007).
Food products and hypersensitivities
Findings suggest that several food products initiate RAU. A significant increase in
cow’s milk antibodies was found among RAU patients compared with healthy
controls, but this difference disappeared when compared with other oral mucosal
diseases  (Thomas  et  al.,  1973).  Gluten  sensitivity  enteropathy  was  found  just  in
2.83% of RAU patients (Shakeri et al., 2009). Other products such as cheese, nuts,
chocolate, azo dyes, flavoring agents, and preservatives, may also contribute to
RAU (Wright et  al.,  1986).  In contrast,  Tarakji  et  al.  found that dietary habits did
not affect RAU (Tarakji et al., 2012).
Trauma
Despite  assumptions  regarding  trauma’s  role  in  RAU  (Wray  et  al.,  1981),  few
trauma studies exist most likely due to ethical and methodological complexities of
such research.
Wray et al. found that mechanical injury may induce RAU in susceptible persons,
but not in healthy controls (Wray et al., 1981). The delivery of traumatic epithelium
may spur the onset of RAU (Aminabadi, 2008).
Bacterial agents
Several studies have examined the aetiological factors or onset of RAU associated
with several types of bacteria. Among these bacteria, Helicobacter pylori
represented the most intensively studied agent due to its role in gastrointestinal
ulcers. The majority of studies failed to find a relationship between Helicobacter
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pylori and RAU, neither in adults (Chapman et al., 1998; Mansour-Ghanaei et al.,
2005; Porter et al., 1997; Shimoyama et al., 2000; Victoria et al., 2003) nor in
children (Fritscher et al., 2004). Only one study found that 23 of 32 (71.8%) RAU
biopsies tested positive for Helicobacter pylori, although this study did not include
biopsies from healthy controls (Birek et al., 1999).
While most studies found no relationship between Helicobacter pylori and RAU,
eradicating the bacterium in RAU patients significantly improved patients’
wellbeing vis-à-vis decreasing RAU episodes and alleviating the intensity of
symptoms (Albanidou-Farmaki et al., 2005; Karaca et al., 2008). Such effects
could, however, result from an increase in vitamin B12 serum (Tas et al., 2013).
Some studies indicated that other bacteria, such as Streptococcus oralis,
Streptococcus sanguis strain 2A, and Streptococcus pyogenes strain M5, play a role
in  the  development  of  RAU  (BARILE  et  al.,  1963;  Donatsky,  1975;  Donatsky,
1976; Donatsky, 1976). Other later studies, however, found no such relationship to
RAU for any of these bacteria (Hoover et al., 1986; Riggio et al., 2000).
Marchini et al. studied the oral microbiota of RAU patients and healthy controls,
finding that the microbiota greatly differs between these two groups (Marchini et
al., 2007).
In addition to the above, from a clinical viewpoint, bacteria are most probably not
the main cause for RAU as RAU is not a contagious disease. Furthermore, RAU
cannot be treated or prevented by systematic antibiotics.
Viral agents
While some scholars suggest that viruses represent causative agents for RAU, no
single virus apears to precipitate RAU. As with the above causative factors, many
studies in this field report conflicting results.
Lin et al. studied the presence of five viruses in RAU biopsy samples from 60
patients and 72 biopsy samples from normal mucosa, finding no viruses in the
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healthy mucosa. However, the following viruses (with the prevalence provided as
percentages) were found in the RAU biopsies: human herpes virus (HHV-8),
26.7%; human cytomegalovirus (HCMV) ,18.3%; Epstein–Barr virus (EBV), 15%;
human papilloma virus (HPV), 13.3%, HSV-1, 6.7%, while HSV-2 not found (Lin
et al., 2005).
Brice et al. suggested that the presence of HHV-6 in the oral mucosa and peripheral
blood of RAU patients may result from normal viral shedding rather than a direct
cause of disease (Brice et al., 2000).
Sun  et  al.  put  forth  another  hypothesis  about  the  role  of  viruses  in  RAU,
hypothesising that EBV-infected epithelial cells are lysed by T-lymphocytes,
leading to ulcer formation (Sun et al., 1998).
HCMV was found only in the pre-ulcerative lesions of RAU and not in healthy
controls  (Sun  et  al.,  1996);  no  significant  difference  in  the  prevalence  of  HCMV
IgG antibodies was detected between RAU patients and healthy participants
(Ghodratnama et al., 1999).
In addition, Pedersen et al. failed to cultivate varicella zoster virus (VZV) from a
RAU lesion, finding instead viral DNA in RAU samples (Pedersen et al., 1993).
That same year and in a different study, Pederson et al. found that the reactivation
of VZV and HCMV may be associated with the recurrence of RAU (Pedersen and
Hornsleth, 1993).
Measles antigens were detected in RAU samples using immunohistochemistry and
they might play a role in down-regulation of CD46 (Czerniniski et al., 2000).
Adenovirus was isolated from herpetiform RAU (Sallay et al., 1973).
Table 2. Aetiological and predisposing factors of RAU.
Predisposing factors Aetiological factors
Age and sex Irritating agents
Heredity Food products and hypersensitivity
Hormonal disturbance Trauma
Haematological disturbance Bacterial agents
Stress and psychological profile Viral agents
Ceasing smoking
Oxidative stress
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2.6. Behçet's disease
RAU may be associated with several systemic diseases as summarized in Table 3.
Behçet's disease represents the most important such disease linked to RAU.
Behçet's disease is a chronic inflammatory multisystem disease characterised by
recurrent ulceration of the oral and genital mucosa which may involve the eyes
(Sakane et al., 1999). In addition, Behçet's disease may affect any of the following
systems: vascular, musculoskeletal, gastrointestinal, genitourinary, and nervous
(Davatchi et al., 2010; Talarico et al., 2010). Behçet's disease has a particularly
high prevalence in those countries situated along what is known as the Silk Road
compared with other countries in Northern Europe and North America (Skef et al.,
2015).  As  with  RAU,  the  cause  of  Behçet's  disease  remains  unknown;  however,
immune dysregulation may play an important role in disease onset (Evereklioglu,
2005). In addition to immune dysregulation, genetic abnormalities highly associate
with Behçet's disease. Several research groups reported a strong association
between Behçet's disease and the HLA-B51 molecule (Hughes et al., 2013; Kirino
et al., 2013; Mizuki et al., 2000; Ohno et al., 1982; Remmers et al., 2010).
Furthermore, Behçet's disease is associated with IL10 and IL23R–L12RB2 in the
Turkish  population,  and  across  the  Middle  East,  Asia,  and  Europe  (Mizuki  et  al.,
2000; Remmers et al., 2010).
Oral mucosa is the most common site involved in Behçet's disease (>90%) and is
characterised by oral ulcerations, which cannot be differentiated from RAU
clinically or histopathologically. To determine a Behçet's disease diagnosis,
patients must experience at least three episodes of RAU over a 12-month period
associated with at least two of the following manifistations: recurrent genital
ulceration, eye involvement, or positive pathergy test.
The management of Behçet's disease differs depending on the affected site and the
severity of the disease. The eye represents the most complicated site (since it may
lead to blindness) followed by nervous system. Most drugs used to treat Behçet's
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disease, such as as azathioprine, infliximab, and ethanercept, address the immune
system (Melikoglu et al., 2005; Sfikakis et al., 2004; Yazici et al., 1999).
RAU and the oral ulcerations associated with Behçet's disease not only share
similarities in their clinical features, but also in the expression of cytokines in the
ulcer  area  given  that  some  of  the  T-helper  (Th)1  cytokines  and  chemokine
receptors increase in both RAU and Behçet's disease oral mucosa. The difference
lies in the Th2 cytokine IL-4, which increases only for Behçet's disease but not in
RAU (Dalghous et al., 2006).
Table 3. Systemic diseases associated with RAU.
Systemic diseases associated with RAU
Behçet’s disease
MAGIC syndrome*
Sweet’s syndrome
Cyclic neutropenia
Benign familial neutropenia
PFAPA syndrome**
HIV
Nutritional deficiencies
Inflammatory bowel disease
Reiter's disease
Ulcus vulvae acutum
* Mouth and genital ulcers with inflamed cartilage syndrome
** Periodic fever with aphthae, pharyngitis and adenitis syndrome
2.7. Oral mucosa
Oral mucosa comprises primarily epithelium and lamina propria and is separated
from the underlying bone and muscular layer by the submucosa (Figure 2).
Depending on the location and function, three types of oral mucosa exist: the
lining, masticatory, and specialised mucosa.
The lining mucosa is covered by non-keratinised stratified squamous epithelium.
The connective tissue for this type is more flexible and elastic than masticatory
mucosa. The lining mucosa covers the lips, cheek, vestibule, free gingiva, and the
soft palate, and is most commonly affected by minor RAU.
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The masticatory mucosa is covered by keratinised stratified squamous epithelium
to protect the underlying tissue from mechanical trauma during mastication. The
masticatory mucosa covers the attached gingiva and the hard palate.
Specialised mucosa represents the third type and covers the tongue.
The superfacial layer of the oral mucosa is composed of stratified squamous
epithelium. The epithelium comprises four layers: stratum basale (basal layer),
stratum spinosum (prickle layer), stratum granulosum (granular layer), and stratum
corneum (keratinised layer) in keratinized epithelium and basal layer, prickle cell
layer, intermediate layer and superficial layer in nonkeratinized epithelium. Oral
epithelial cells represent 90% of the oral epithelium cells, while melanocytes,
Langerhans cells, and some inflammatory cells represent 10%.
While the epithelium protects the underlying tissue from external irritation and
microbial invasion, the lamina propria supports the oral mucosa and provides
nutrients to the epithelial cells. Several types of cells are present in the lamina
propria, including fibroblast, endothelial cells, mast cells, macrophages, and other
immune cells such as lymphocytes and plasma cells. All of these cells are
immersed in an amorphous ground substance.
The submucosa shares similar features with the lamina propria, but differs in its
loose fatty tissue, glandular cells, major blood vessels, and nerves which supply the
oral mucosa. In some areas of the hard palate and attached gingiva, submucosa
disappear and the oral mucosa is directly attached to the underlying bone.
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Figure 2. Histological features of oral mucosa.
2.8. Inflammatory cells in RAU
Neutrophils
Neutrophils represent the most abundant white blood cells making up 40% to 70%
of all white blood cells. Neutrophils serve as essential elements of innate immunity
since these cells are the first to arrive at an inflammation site. Neutrophil cytoplasm
contains granules filled with premade microbicidal substances, such as proteolytic
enzymes ready for release to attack microbes.
Neturophils highly infiltrate the RAU ulcer area, participating not just in killing the
microbes, but also in destroying the surrounding tissue through the release of
proteolytic enzymes (Hayrinen-Immonen et al., 1991; Hayrinen-Immonen et al.,
1993; Mills et al., 1980).
Two studies on the spontaneous migration of neutrophils in RAU patients yielded
different results. While Dagalis et al. found no difference between RAU patients
and controls in terms of neutrophil migration (Dagalis et al., 1987), Sistig et al.
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found that spontaneous neutrophil migration significantly decreased in RAU
patients compared with healthy controls (Sistig et al., 2001).
Furthermore, the phagocytic activity of neutrophils taken from the peripheral blood
and saliva of RAU patients is significantly lower compared with the neutrophils
taken from healthy controls (Kumar et al., 2010).
Oxygen radicals produced from neutrophils in RAU patients did not differ from the
neutrophils in contorls (Wray and Charon, 1991).
Thus, severe infiltration of neutrophils in the ulcer area might indicate the
importance of neutrophils in aggravating the inflammation during RAU episode.
Macrophages
When monocytes leave the blood and enter tissue, they proliferate becoming
resident macrophages. Resident macrophages form a group of different types of
macrophages determined by their location, with each type having its own name.
Macrophages play an important role in both innate and adaptive immunity, but the
most important function includes scavenging apoptotic bodies and cellular debris
under normal conditions; during inflammation, especially during chronic phases of
inflammation, macrophages also engulf microbes and clean the area of dead
neutrophils, normally appearing during the acute phase of inflammation.
In RAU, macrophages may appear in the lamina propria representing a high
percentage of the total immune cell infiltratation especially during the early stage
of RAU (Regezi et al., 1993).
Regezi et al. suggested that the endothelial leukocyte adhesion molecule and
intercellular adhesion molecule-1 attract macrophages to the RAU lesion, since
both stained strongly in the endothelial cells of early RAU lesions. The staining
intensity gradually decreased toward the periphery of the lesion (Regezi et al.,
1993).
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Mast cells
A mast cell is a tissue-resident immune cell first discovered by Paul Ehrlich in
1878.
Mast cells play a major role in several diseases through the release of inflammatory
molecules, such as histamine and TNF-α, which are preformed and preserved in a
high concentration in granules.
The number of mast cells significantly increase in RAU lesions comparing
traumatic ulcers and healthy controls, representing 2% to 5% of the total number of
immune  cells  in  RAU  (Hayrinen-Immonen  et  al.,  1991;  Natah  et  al.,  1998;
Schroeder et al., 1983). Mast cells in RAU show signs of degranulation, which
support their importance in RAU lesion (Natah et al., 1998). Mast cells have also
been identified as a major source of TNF-α in RAU lesions (Natah et al., 1998).
Lymphocytes
Lymphocytes form an important constituent of the white blood cell count since
they are regarded as the basic units of adaptive immunity.
Three  major  types  of  lymphocytes  exist:  T  cells,  B  cells,  and  natural  killer  (NK)
cells. While T cells are responsible for cell-mediated immunity, B cells are
involved in humoral immunity. NK cells primarily participate in innate immunity
by killing tumor cells and cells infected with viruses,  while also playing a role in
adaptive immunity.
In 1980, Mills et al. first suggested the role of lymphocytes in RAU, finding that
the preulcerative lesion and margins of the developing ulcer contained lymphocytes
(Mills et al., 1980).
Several studies focused on the changes in the pattern of lymphocyte types in the
lamina propria of the ulcer area and in the peripheral blood of RAU patients. These
studies have not always agreed with one another. In two studies, significantly fewer
helper T cells (CD4) were found in the lamina propria and peripheral blood of
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RAU patients compared with healthy controls (Pedersen et al., 1991; Savage et al.,
1988). But, in a third study, no difference was found in the percentage of CD4 cells
between RAU patients and healthy controls (Pedersen et al., 1989).
Cytotoxic T cells (CD8) significantly increased (Pedersen et al., 1989; Pedersen et
al., 1992; Savage et al., 1988) or did not differ in the lamina propria and peripheral
blood of RAU patients compared with healthy controls (Pedersen et al., 1991;
Sistig et al., 2001).
Signficantly fewer B cells (CD19) in the active phase of a RAU lesion were found
compared with the remission phase (Sistig et al., 2001). This difference, however,
was  not  found  in  another  study  comparing  the  number  of  B  cells  (CD19)  in  the
peripheral blood of RAU patients during an active ulcer episode to those in healthy
controls (Bachtiar et al., 1998).
Although no difference was found in the number of NK cells in the peripheral
blood of RAU patients compared with healthy controls (Bachtiar et al., 1998), the
activity of NK cells extracted from RAU patients was significantly lower than that
in healthy controls (Sistig et al., 2001).
These results may indicate that an immunological disturbance, represented by an
abnormal pattern of lymphocyte distribution in the peripheral blood or in the
lamina propria of ulcer area,  may play a role either in the onset or progression of
RAU.
2.9. Molecular aspects
Toll-like receptors (TLRs)
TLRs comprise a group of receptors belonging to the pathogen-recognition receptor
(PRRs) family and play a major role in innate immunity (Akira and Takeda, 2004).
Thus far, 13 TLRs have been identified. The toll receptor was first identified in
Drosophila melanogaster; the first function identified for TLRs included the
development and differentiation of the Drosophila embryo (Anderson et al., 1985;
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Anderson et al., 1985). In 1996, Hoffmann et al. showed that the activation TLRs
lead to the production of the antifungal peptide ‘drosomycin’ which is important in
protecting fruit flies from fungal infections (Hoffmann et al., 1999). This discovery
proved that the toll receptor features a dual life: one during the development of an
embryo and the second during the life of Drosophila melanogaster. In 1991, Gay
and Keith showed that the cytoplasmic domain of the toll receptor is similar to the
cytoplasmic domain of the mammalian IL-1R (Gay and Keith, 1991), named the
toll-IL-1 receptor (TIR) (Medzhitov et al., 1997). Since that time, mammalian
TLRs were found. While these receptors share cytoplasmic components with IL-
1R, they differ markedly from the extracellular region, and IL-1R features a
immunoglobulin-like domain in its extracellular region. Finally, TLR contains
leucin-rich repeats (Poltorak et al., 1998).
The discovery of TLRs may be regarded as revolutionary in our understanding of
the working mechanisms of innate immune systems. For many years, the question
of how our body in general and specifically our inflammatory cells recognise
microbes or distinguish non-self-molecules from self-molecules and react against
them remained unanswered. Scholars assumed that the innate immune cells reacted
against microbes in a non-specific manner, while adaptive immune cells reacted in
a specific manner. With the discovery of PRRs, the concept changed along with the
realisation that these receptors recognise and bind to highly conserved structures of
microbes, such as lipopolysaccharide (LPS), lipoproteins, and nucleic acids, in a
specific way. Furthermore, PRRs may also recognise and bind to self-molecules
usually preserved inside cells, but are either passively released or actively secreted
during pathological conditions in order to alert the immune system. For this reason,
these molecules are called alarmins or damage-associated molecular patterns
(DAMPs).
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TLR classification and signalling pathways
Since  the  discovery  of  TLR4  as  a  receptor  for  LPS,  10  and  13  TLRs  have  been
identified in humans and mice, respectively. In humans, 9 of 10 TLRs possess
known ligands and signaling pathways, while the ligands and signaling pathways
for TLR10 remain as yet unknown (Table 4).
TLRs are expressed in most mammalian cells starting from the inflammatory cells,
such as macrophages, neutrophils, mast cells, and lymphocytes among others, as
well as in non-inflammatory cells such as epithelial cells and fibroblasts (Akira et
al., 2006).
Members of the TLR family were divided into two groups depending on the
cellular  location  of  the  receptor.  TLR1,  TLR2,  TLR4,  TLR5,  TLR6,  and  TLR10
are located on the cell membrane and recognise microbial structures located on the
external surface of the microbes such as LPS and flagellin. The second group of
TLRs include TLR3, TLR7, TLR8, and TLR9, which are located in the cytoplasm
and recognise microbial nucleic acids (Kawai and Akira, 2010). Stimulation of
TLRs with pathogen-associated molecular patterns (PAMPs), microbe-associated
molecular patterns (MAMPs), or DAMPs may activate the cells and lead to the
production of chemokines, pro-inflammatory cytokines, and antimicrobial peptides.
The majority of TLRs work as homodimers, except TLR2 which creates
heterodimer complexes with TLR1, TLR6, or TLR10 (Farhat et al., 2008). These
heterodimers recognise different subtypes of lipopeptides. While TLR2/TLR1
heterodimers recognise triacylated lipopeptides, TLR2/TLR6 heteropeptides
recognise diacylated lipopeptides (Farhat et al., 2008).
Regarding the signaling pathways, all TLRs except TLR3 and TLR4 work through
myeloid differentiation factor 88 (MyD88). In addition to MyD88, TLR4 use TIR
domain-containing adapter-inducing interferon-β (TRIF) in its signaling pathway.
TLR3 is the only receptor in this family which uses TRIF signaling pathways
(Kawai and Akira, 2010).
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Table 4. Summary of human TLR cellular localisations, signalling adaptors, examples of TLR
ligands, and induced effector cytokines.
Receptor Cellular
localisation
Signalling
adaptor
Ligand
PAMP                                     DAMP
Effector cytokines
induced
TLR1/2 Cell
membrane
TIRAP,
MyD88
Triacyl lipopeptides Inflammatory cytokines
(TNF-α, IL-6, etc.)
TLR2 Cell
membrane
TIRAP,
MyD88
Peptidoglycan
Porphyromonas
gingivalis LPS
Bacteroides fragilis
LPS
Lipoteichoic acid
Lipoarabinomannan
Zymosan
HSPs
HMGB1
Uric acid
Biglycan
Hyaluronan
Versican
Inflammatory cytokines
(TNF-α, IL-6, etc.)
TLR3 Endosome TRIF ssRNA
dsRNA
RNA Inflammatory cytokines
(TNF-α, IL-6, etc.), type I
IFNs
TLR4 Cell
membrane
TIRAP,
MyD88,
TRAM and
TRIF
LPS
Mannan
Envelope proteins
HSPs
HMGB1
Uric acid
Biglycan
Hyaluronan
sulphate
Tensacin-C
Fibrinogen
Fibronecting
Surfactant
Β-defensin
Inflammatory cytokines
(TNF-α, IL-6 etc.), type I
IFNs
TLR5 Cell
membrane
MyD88 Flagellin Inflammatory cytokines
(TNF-α, IL-6, etc.)
TLR6/2 Cell
membrane
TIRAP,
MyD88
Diacyl lipopeptides
Lipoteichoic acid
Zymosan
Inflammatory cytokines
(TNF-α, IL-6, etc.)
TLR7 Endosome MyD88 ssRNA RNA Inflammatory cytokines
(TNF-α, IL-6, etc.), type I
IFNs
TLR8 Endosome MyD88 ssRNA RNA Inflammatory cytokines
(TNF-α, IL-6, etc.), type I
IFNs
TLR9 Endosome MyD88 dsDNA
CPG-DNA
DNA Inflammatory cytokines
(TNF-α, IL-6, etc.), type I
IFNs
TLR10 Cell
membrane
Data are taken from (Akira and Takeda, 2004; Akira et al., 2006; Erridge, 2010; Kawai and Akira,
2010; Kono and Rock, 2008; Kumar et al., 2009).
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TLRs in oral mucosal diseases
Human oral epithelial cells form a physical barrier against mechanical irritation and
microbial invasion. In addition, these cells have 10 TLRs (TLR1–10) forming a
second line of defence against microbial invasion (Ali et al., 2008). The expression
of TLRs was studied in relation to several oral diseases, such as oral lichen planus,
chronic hyperplastic candidiasis, periodontitis, oral epithelial dysplasia, and oral
squamous cell carcinoma (Ahmed Haji Omar et al., 2015; Ali et al., 2008; Beklen
et al., 2008; Janardhanam et al., 2012; Kotrashetti et al., 2013; Siponen et al.,
2012). In these studies, the expression of TLRs did not possess the same pattern
being instead disease-dependent. TLR2 and TLR4 mRNA expression in the oral
mucosal brush samples from Behçet's disease and RAU patients were compared
with healthy controls. Both showed significantly higher concentrations in patients
experiencing Behçet's disease relapses, while no difference was found in the RAU
samples  (Seoudi  et  al.,  2014).  Gallo  et  al  reported  that  TLR2  mRNA  expression
was significantly elevated in RAU tissue samples while TLR3 and TLR5 mRNA
exresson was declined  when compared with healthy controls (Gallo et  al.,  2012).
Additionally, the peripheral blood mononuclear cells (PBMCs) of RAU patients
differed in their response to TLR ligands compared with healthy control, PBMCs
of RAU patients showed a higher response to heat-killed Listeria monocytogenes
(HKLM) and a lower response to lipoteichoic acid (LTA; (Borra et al., 2009).
High-mobility group box 1 (HMGB1)
HMGB1, a non-histone nuclear protein present in almost all mammalian cells,
features a dual life. One life takes place inside the cell participating in transcription,
replication, and cellular differentiation during cell division. The second life resides
outside the cell when it is actively secreted or passively released during cell death,
which works as an inflammatory mediator. The role of HMGB1 in mediating
inflammation was first reported by Wang et al. in 1999, finding that cultured
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murine macrophages secrete HMGB1 to the supernatant after stimulation with
LPS, TNF-α, and IL-1β in a time-dependent manner. HMGB1 also increased in
mice serum after mice were exposed to LPS (Wang et al., 1999). As a result of this
discovery, HMGB1 was regarded as a late-stage mediator of inflammation and
classified as a DAMP.
HMGB1 is located inside the nucleus in most cells, with the ability to continuously
shuttle between the nucleus and the cytoplasm in some cells as neutrophils (Ito et
al., 2007). HMGB1 is actively secreted by inflammatory cells such as
macrophages, monocytes, NK cells, dendritic cells, endothelial cells, and platelets
after activation (Harris et al., 2012). During cell activation, HMGB1 undergoes
post-translation modification, that is, phosphorylation and acylation. Some of these
changes affect the binding of HMGB1 to DNA and prevent HMGB1 from entering
the nucleus again, leading to the accumulation of HMGB1 in the secretory
lysosomes before secretion to the extracellular matrix (Ito et al., 2007; Youn and
Shin, 2006).
HMGB1 may also be passively released to the extracellular matrix during cell
necrosis. Some controversy exists regarding the release of HMGB1 from apoptotic
cells, since early studies claimed that HMGB1 is stored inside apoptotic bodies
during cell apoptosis. Later studies found that HMGB1 is released in an oxidised
form (inactive form) as a result of oxidation by mitochondrial reactive oxidative
species (ROS) (Andersson and Tracey, 2011; Kazama et al., 2008).
A significant improvement in our understanding of the effects of extracellular
HMGB1 on mammalian cells resulted from a study by Venereau et al. in 2012,
when they discovered activity differences between the three redox forms of
HMGB1 (Venereau et al., 2012).
While all-thiol HMGB1 works as a recruiting agent for leucocytes, disulfide-
HMGB1 stimulates macrophages to produce chemokines such as IL-8 and pro-
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inflammatory cytokines such as TNF-α and IL-6. The final redox form is terminally
oxidised and regarded as inactive (Venereau et al., 2012).
Differences in the redox form also affect the binding of HMGB1 to its receptors.
All-thiol HMGB1 forms a complex with C-X-C motif chemokine 12 (CXCL12;
HMGB1-CXCL12 heterocomplex) which later to binds C-X-C chemokine receptor
type 4 (CXCR4) and leads to the recruitment of inflammatory cells. After the
formation of an intramolecular bond, HMGB1 loses its ability to bind with
CXCL12 leading to the inhibition of its chemotaxis effect. Disulfide-HMGB1
binds to TLR4 and activates the nuclear factor kappa-light chain enhancer of
activated B cells (NF-κB) through an MyD88-dependent mechanism leading to cell
activation and the production of pro-inflammatory cytokines and chemokines
(Venereau et al., 2012). In addition to its role in inflammation, HMGB1 in
association with p53 may regulate the balance between apoptosis and autophagy.
p53 knockout colon epithelial HCT116 cells increase the cytosolic HMGB1, which
is associated with an increased autophagy and decreased apoptosis. In contrast,
HMGB1  knockout  cells  increase  the  cytosolic  p53,  which  is  associated  with  an
increasing apoptosis and decreasing autophagy (Kristen et al., 2012).
Redox forms also differ depending on the location of HMGB1. While in the resting
state, HMGB1 remained inside the cells usually in the all-thiol form; that which is
secreted may appear in any of the three forms. It was also reported that in
acetaminophen-induced liver injury, the chemotactic all-thiol HMGB1 was
elevated first in mice serum leading to the recruitment of inflammatory cells. This
is regarded as the first step of inflammation, followed by an increase in the level of
inflammatory mediator disulfide-HMGB1 in the serum. When the liver
inflammation resolved, the C106 terminally oxidised HMGB1 predominated in
mice serum (Antoine et al., 2010; Antoine et al., 2012; Yang et al., 2013).
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HMGB1 in oral mucosal diseases
As HMGB1 is a relatively newly discovered inflammatory mediator, its function in
oral diseases remains insufficiently studied. In this context most of the papers have
been focused on HMGB1 role in  in periodontitis. Ligature- or LPS-induced
periodontitis in rats have been associated with the increase in the HMGB1 mRNA
(Nogueira et al., 2014). In human chronic periodontitis, HMGB1 mRNA
significantly increased when compared with control gingival tissue (Luo et al.,
2011). This increase was also associated with the translocation of HMGB1 from
the nucleus in healthy gingival epithelial cells to the cytoplasm in periodontitis
gingival epithelial cells (Ebe et al., 2011).
Interleukin-17C (IL-17C)
IL-17C was discovered in 2000 by Li et al. (Li et al., 2000). IL-17C was classified
as a member of the IL-17 family, a group of cytokines that play an important role
in the human immune system through the activation of mammalian cells to produce
pro-inflammatory cytokines, chemokines, and antimicrobial peptides (Table 5). IL-
17A was the first member of this family identified, which then expanded to inlcude
five  additional  members  to  form  a  family.  Six  cytokines  work  through  five
different receptors, which include IL-17RA–RE (Pappu et al., 2012). IL-17A and
IL-17F are the best-known cytokines from this family, and have been studied
intensively in relation to several autoimmune and inflammatory diseases, primarily
rheumatoid arthritis and psoriasis (Iwakura et al., 2011). Other members of this
family have clearly received less attention. Studying the effect of IL-17C and its
active mechanisms largely began after the discovery that epithelial cells represent
the primary producers of this cytokine (Ramirez-Carrozzi et al., 2011).
IL-17C exerts its effect through binding to the IL-17RA and IL-17RE
heterodimers, where the affinity to bind to IL-17RE is higher than that in IL-17RA
(Ramirez-Carrozzi et al., 2011). However, both are needed to stimulate cells.
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Scholars found that blocking IL-17RA in human primary keratinocytes led to an
inhibition in the production of granulocyte colony-stimulating factor (G-CSF) and
beta defensin (BD)-2 in a concentration-dependent manner. Similarly, IL-17RE as
fibroblasts failed to respond to IL-17C despite having IL-17RA while lacking IL-
17RE (Ramirez-Carrozzi et al., 2011).
The importance of IL-17C was identified when the TLR2 and TLR5 ligands were
found to stimulate the epithelial cells to produce IL-17C. This effect was not found
for other IL-17 family members. In addition to PAMPs, pro-inflammatory
cytokines such as TNF-α and IL-1β also activate epithelial cells to produce IL-17C
(Ramirez-Carrozzi et al., 2011).
In vivo and in vitro studies showed that IL-17C carries both beneficial and
detrimental effects. IL-17C and IL-17RE knockout mice suffered severe weight
loss and a huge bacterial burden, and none survived after challenged by bacteria
(Reynolds  et  al.,  2012).  The  stimulation  of  epithelial  cells  with  IL-17C  led  to  a
significant increase in the production of antimicrobial peptides (Ramirez-Carrozzi
et al., 2011). This evidence clearly indicate that IL-17C is quite important in the
defence against microbial challenges. For this reason, the idea that IL-17C may
provide sufficient defence in the epithelium tissue during weak microbial
challenges was put forth, without recruiting inflammatory cells and without
producing pro-inflammatory cytokines.
However, this was simply identified as the first phase of IL-17C; the second phase
appears as a severe inflammation. In such cases, IL-17C stimulates human cells,
especially epithelial cells since few have IL-17RE. This results in the production of
pro-inflammatory cytokines and chemokines, which later work to recruit
inflammatory cells ultimately leading to severe inflammation and the destruction of
the tissue.
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Table 5. Summary of human IL-17 family members, receptors, and their producing cells.
IL-17 member IL-17 receptor Producing cells
IL-17A IL-17RA/IL-17RC CD4+ T cell, CD8+ T cell, γδ, T cell, NKT cell, neutrophil and
paneth cell.
IL-17B IL-17RB Chondrocyte, neuron, cells of the gastrointestinal tract, and
pancreas.
IL-17C IL-17RE/IL-17RA Keratinocyte, CD4+ T cell, dendritic cells, and Macrophage.
IL-17D unknown CD4+ T cell and B cell
IL-17E IL-17RA/IL-17RB CD4+ cell, CD8+ T cell, mast, cell, eosinophil, epithelial cell and
endothelial cell
IL-17F IL-17RA/IL-17RC CD4+ cell, CD8+ T cell, γδ, T cell, NKT cell, LTi-like cell,
and epithelial cell
Modified from Iwakura et al (Iwakura et al., 2011).
IL-17C in oral mucosal diseases
While IL-17C plays a major role in the regulation of the epithelial immunity
(Ramirez-Carrozzi et al., 2011), its role in oral diseases has received insufficient
attention. IL-17C and its receptor IL-17RE have not been found of  importance  in
the immunity against oral and cutaneous Candida infections (Conti et al., 2015).
Because IL-17A received primary attention in comparisons with other IL-17 family
cytokines, this was also the case in oral mucosal diseases. IL-17A is overexpressed
in oral lichen planus and chronic periodontitis compared with healthy controls (Lu
et al., 2014; Mitani et al., 2015). In addition, patients with a IL-17A production
defect or IL-17A autoantibodies suffer from chronic mucocutaneous candidiasis
(Conti et al., 2011; Kisand et al., 2010). The IL-17A defence mechanism against
Candida infection is primarily dependent on the induction of antimicrobial peptides
(AMPs; (Trautwein-Weidner et al., 2015).
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Beta 2 defensin (BD-2)
Defensins form a group of endogenous cystin-rich AMPs, regarded as the largest
group of the AMPs family (Dale and Krisanaprakornkit, 2001). Defensins are
cationic peptides with a molecular mass of 3.5 to 4.5 KD (Bals, 2000). Defensins
possess two terminals: an amino terminal which works mainly against gram
positive bacteria and a carboxyl terminal which works against gram negative
bacteria (Zhu and Gao, 2013).
Defensins are divided into three main groups: α, β, and θ (the newest member of
the family) (Pazgier et al., 2006). Each of these three groups has their own family.
BD is the most important member of the defensin family given that the mucosa is
produced primarily from epithelial cells and is regarded as a part of the first-line
defence against microbial invasion (Bals, 2000).
Several  forms  of  BDs  were  identified,  while  the  first  three  (BD-1,  -2,  and  -3)
represent the most well-known, more intensively studied members. Because BD-1
is constantly expressed by the epithelial cells in healthy and in inflamed tissue, it is
regarded as a static defence mechanism. BD-2 and BD-3 are secreted only after
activation of the epithelial cells and are expressed primarily in inflamed tissue and
sometimes at a very low level in healthy tissue (Gursoy and Kononen, 2012).
BD-2 is an inducible AMP which works primarily against gram negative bacteria.
BD-2 was first identified in humans in 1997 when it was purified from the skin of
psoriasis patients (Harder et al., 1997). Several agents may induce BD-2
production. These agents may be divided into microbial products as gram negative
bacteria, candida, and others; and pro-inflammatory cytokines may include
interferon gamma (IFN-γ), TNF-α, IL-1β, IL-6, IL-17, and IL-22 (Kanda et al.,
2011). Both NF-κB and activator protein 1 (AP-1) play a major role in the
induction of BD-2 since it shares several binding sites with them (Fellermann and
Stange, 2001).
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BD-2 has several functions. It is primarily known as a killing tool against microbes
by attacking the microbial membrane and forming multimeric pores (Bals, 2000).
Surprisingly,  studies showed that BD-2 may accomplish more than simply killing
microbes since it was found to work as a chemotaxis agent for neutrophils, mast
cells,  and other inflammatory cells (Diamond and Ryan, 2011).  In addition, BD-2
helps in the healing of wounds through increasing the migration of keratinocytes.
This may explain the significant increase in BD-2 expression at the wound edge.
Such an increase in this expression may result from the synergistic effect of the
epidermal growth factor (EGF) and IL-1α (Diamond and Ryan, 2011).
Since the identification of the first AMP, many researchers assumed that these
peptides could serve as new antibiotics. By using them, we may overcome the
problem of microbial resistance, which is regarded as a serious problem especially
as the number of such microbes continuously increases. Unfortunately the use of
AMPs was not so successful and most of them were failed to pass the clinical trials
mainly because of the high cost and also because no significant difference was
found between AMPs and synthetic antibiotics. Despite these unsatisfying results
for some AMPs, clinical trials for other AMPs continue. Magainin peptide, which
is now in the third phase of clinical trials for the treatment of diabetic foot ulcers,
may  represent  the  first  AMP  released  on  the  market  (Fox,  2013;  Gordon  et  al.,
2005).
BD-2 in oral mucosal diseases
BD-2 is an inducible AMP expressed only in inflamed tissue (Gursoy and
Kononen, 2012). BD-2 mRNA increases in the oral mucosa of gingivitis and
periodontitis compared with control oral mucosa (Dommisch et al., 2005). At the
protein level, BD-2 is found to be increased in Candida infected  oral mucosa of
patients with recurrent respiratory papilomatosis (Chong et al., 2006; Sawaki et al.,
2002). Additionally, salivary BD-2 level have been increased in patients with oral
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lichen planus, Behçet's disease, and RAU compared with healthy controls and
returns to a normal level after treatment (Kucukkolbasi et al., 2013).
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3. Aims of the study
The principal aim of this study was to identify the most important steps in the
initiation and down-regulation of the inflammation in RAU lesions and the role of
oral epithelial cells in this process.
In order to achieve the principal aim of this study, we focused on addressing four
specific aims:
A) To study the mechanism of oral epithelial cell death in RAU and the effects of
this on the adjacent cells.
B) To  study  the  pattern  of  TLR  expression  in  RAU  lesions  and  compare  this
expression to that in healthy controls.
C) To study the expression of selected chemokines, pro-inflammatory cytokines,
and antimicrobial peptides in RAU lesions and compare this expression to that
in healthy controls.
D) To study the response of oral keratinocytes to pro-inflammatory cytokines in
terms of TLR up-regulation and in terms of chemokine, pro-inflammatory
cytokine, and antimicrobial peptide production.
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4. Patients and methods
4.1. Patients
We selected 13 subjects suffering aphtae and 11 healthy controls for inclusion in
this  study.  We  took  biopsy  samples  from  the  aphtae  lesions  from  8  men  and  5
women (mean age of 33.7 years, range of 10 to 63 years). The lesions were taken
from labial and buccal mucosa, with the ulcer duration ranging from 4 to 7 days.
We only included minor RAUs in this study, taking biopsies only from ulcers
which fulfilled the criteria of minor RAU, which were round or oval in shape,
measuring less than 10 mm in diameter, appearing yellow or gray in colour,
recurring, and surrounded by a red erythematous halo area.
We took control samples from healthy oral mucosa from 4 men and 7 women
(mean age of 31.2 years, range of 12 to 67 years) during wisdom and canine tooth
extraction. A specialised oral surgeon performed all biopsies under local anesthesia
(xylocaine-adrenaline, 20 mg/ml 12.5 μg/ml). Samples were preserved in 10%
formalin and then embedded in paraffin blocks according to a standard protocol.
The  study  protocol  was  approved  by  the  ethics  committee  of  the  Institute  of
Dentistry, University of Helsinki (Dnro 109/13/03/02/2012). Patient participation
was voluntary and all patients signed an informed consent form.
To avoid secondary RAU, all patients suffering from Behçet's disease, periodic
fever, cyclic neutropenia, Reiter’s syndrome, Sweet syndrome, an
immunodeficiency such as human immunodeficiency virus (HIV), or recent viral
infections were excluded from the study. Patients receiving topical or systemic
treatment with corticosteroids or taking any medications that affect the RAU cycle
were also excluded from the study.
Neither patients nor controls had an iron, vitamin B12, or folic acid deficiency, and
none were using drugs known to induce aphthae, such as methotrexate.
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4.2. Methods
4.2.1. Cell culture
Human oral primary keratinocytes (HOK)
Human oral primary keratinocyte cells and keratinocyte culture medium were
purchased from Science Cell Research Laboratory (Science Cell Research
Laboratory, Carlsbad, CA, USA). The cell culture medium was supplemented with
oral keratinocyte growth supplement and a 500 unit/ml of penicillin/streptomycin
solution. Cells were cultured in a 75 T-flask until 80% confluent was achieved. For
stimulation, cells were harvested by adding trypsin-ethylenediaminetetraacetic acid
(EDTA),  and  were  then  seeded  in  a  24-well  plate  with  a  density  of  5  x  104
cells/well.  The  cells  were  exposure  to  different   human  proteins   as  outlined  in
Table 6.
Human oral keratinocyte SCC-25 cell line
The SCC-25 (ATCC® CRL-1628™) cell line is derived from tongue cancer and
was purchased from American Type Culture Collection (ATCC, Manassas, VA,
USA). Cells were grown in a 10-cm dish supplemented with Dulbecco's Modified
Eagle Medium (DMEM)-12 (Gibco, Payisley, UK), 10% fetal bovine serum, 1000
U/ml penicillin, and 0.1 mg/ml streptomycin. At 80% confluence, the cells were
detached by trypsin-EDTA and plated in a 24-well plate at 1 x 105 cells/well. Table
6 summarises the protein concentrations and the duration of the stimulations.
Human primary gingival fibroblasts
Human primary gingival fibroblasts were isolated using the explant culture
technique (Konttinen et al., 1989). Cells were grown in a 10-cm dish containing
RPMI-1640 medium (Lonza, Basel, Switzerland) with 10% fetal bovine serum, L-
glutamine, 1000 U/ml penicillin, and 0.1 mg/ml streptomycin. The cells were
detached with trypsin-EDTA and seeded in a 12-well plate at a density of 8 x 104
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cells as decribed above. Table 5 summarises the protein concentrations and the
duration of the stimulations. Table 6 describes the cell exposure to different human
proteins.
Table 6. Details of the protein concentrations and duration of stimulations used in this study.
Protein Concentration Duration (hours) Company Study
All-thiol-HMGB1 1000 ng/ml 8, 24 R&D system I
Di-sulfide-HMGB1 1000 ng/ml 8, 24 R&D system I
IL-17C 100 ng/ml 8, 24
24
R&D system1 III
 IV
IFN-? 50 ng/ml 8, 24 R&D system I
LPS 10 ng/ml 24 R&D system I
Self-DNA 50 ng/ml 8, 24 Extracted from SCC-25
cells
I
TNF-? 10 ng/ml
50 ng/ml
4
24
R&D system I
IV
Vitamin K3 10 μM 24 Sigma2 IV
1) R&D system, Minneapolis, MN, USA.
2) Sigma, St. Louis, MO, USA.
4.2.2. Immunohistochemistry
Formalin fixed and paraffin embedded tissue samples were cut to a 4-μm thickness
and incubated overnight at 37°C. For the first study, the slides were stained with an
automated robot machine (Leica BOND-MAX, Leica Microsystems, Wetzlar,
Germany). The machine was supplied with a bond-polymer refined detection kit for
staining and a citrate buffer solution for antigen retrieval. According to the selected
protocol, the slides were incubated for 20 min in the citrate buffer, 60 min in the
primary antibody, 30 min in the post primary, 30 min in the polymer, 10 min in
0.023% 3,3’-diaminobenzidine tetrahydrochloride (DAB), and 5 min in
hematoxylin. The slides were washed with a washing buffer (supplied from the
company) between steps.
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For the other three studies, a manual staining protocol from VECTASTAIN ABC
Systems (Vector Laboratories, Burlingame, CA) was used. The slides were first
deparaffinised, and antigens were retrieved in a citrate buffer (pH 6.0) under a
microwave for 25 min (MicroMED T⁄T Mega Histoprocessing Labstation;
Milestone Srl, Sorisole, Italy). Endogenous peroxide was blocked using 3% H2O2
in a phosphate-buffered saline (PBS) for 10 min. A nonspecific background
staining was blocked by incubating the slides with a 10% normal serum for 1 h at
room temperature (RT). Then, the slides were incubated with primary antibodies
(Table 7) overnight at +4°C. The next day, the slides were incubated with biotin-
conjugated secondary antibody for 1 h at RT. Then, they were incubated with an
avidin–biotin complex for 1 h at RT. To develop the colour, 0.006% hydrogen
peroxide  substrate  and  DAB  chromogen  were  added  to  the  slides,  and  the  slides
were incubated for 10 min at RT. Hematoxylin staining was used to stain the cell
nuclei. Between steps, the slides were washed three times for 5 min each with PBS
or 0.5% Triton X-100 diluted in PBS.
For negative staining of controls, slides were incubated with a non-immune IgG at
the same concentration, the same incubation time, and in the same environment as
the primary antigen-specific antibodies.
4.2.3. Immunofluorescence
Paraffin-embedded tissue sections and cultured cells on coverslips were
permeabilised with 0.5% Triton X-100 for 10 min before incubating them in a 10%
normal serum for 1 h at RT. The slides and coverslips were incubated with primary
antibodies overnight at +4°C (Table 7). Then, they were incubated with
fluorescein-conjugated secondary antibodies for 1 h at RT. Nuclear staining relied
on 4'6-Diamidino-2-phenylindole (DAPI) for 10 min at RT. Finally, samples were
mounted in Vectashield® (Vector Laboratories, Burlingame, CA) and kept at +4°C
39
in a dark place. The slides and coverslips were washed three times with PBS for 5
min each between steps.
For the negative staining of controls, slides were incubated with a non-immune IgG
at the same concentration, the same duration, and in the same environment as the
primary antigen-specific antibodies.
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Table 7. Detailed information about the antibodies used in this study.
Antibody Type Company Concentration Staining method Study
4HNE Polyclonal
rabbit IgG
Abcam1 2 μg/ml Immunohistochemistry IV
BD-2 Polyclonal
rabbit IgG
Bioss2 2 μg/ml
4 μg/ml
Immunohistochemistry
Immunofluorescence
IV
IV
Caspase-3 Polyclonal
rabbit IgG
Cell Signaling
Technology Inc.3
0.5 μg/ml Immunohistochemistry I
CD68 Monoclonal
mouse IgG1
DAKO4 1 μg/ml Immunofluorescence IV
HMGB1 Monoclonal
mouse IgG1
Abnova5 1 μg/ml
10 μg/ml
Immunohistochemistry
Immunofluorescence
I
I
IL-8 Polyclonal
goat IgG
Santa Cruz6 0.2 μg/ml Immunohistochemistry III
IL-17A Polyclonal
goat IgG
R&D 1 μg/mL
5 μg/mL
Immunohistochemistry
Immunofluorescence
III
III
IL-17C Polyclonal
goat IgG
R&D 1 μg/mL Immunohistochemistry III
MCT Monoclonal
mouse IgG1
AbD Serotec7 0.1 μg/ml Immunofluorescence III, IV
TLR1 Polyclonal
rabbit IgG
Santa Cruz
Biotechnology
0.8 μg/mL Immunohistochemistry II
TLR2 Polyclonal
rabbit IgG
Santa Cruz
Biotechnology
2.6 μg/mL
2 μg/mL
Immunohistochemistry
Immunofluorescence
II
I
TLR3 Polyclonal
rabbit IgG
Santa Cruz
Biotechnology
2 μg/mL Immunohistochemistry II
TLR4 Polyclonal
rabbit IgG
Santa Cruz
Biotechnology
1.3 μg/mL
2 μg/mL
Immunohistochemistry
Immunofluorescence
II
I
TLR5 Polyclonal
rabbit IgG
Santa Cruz
Biotechnology
1.3 μg/mL Immunohistochemistry II
TLR6 Polyclonal
goat IgG
Santa Cruz
Biotechnology
1 μg/mL Immunohistochemistry II
TLR7 Polyclonal
goat IgG
Santa Cruz
Biotechnology
0.8 μg/mL Immunohistochemistry II
TLR8 Polyclonal
rabbit IgG
Santa Cruz
Biotechnology
1 μg/mL Immunohistochemistry II
TLR9 Polyclonal
rabbit IgG
Santa Cruz
Biotechnology
0.5 μg/mL Immunohistochemistry II
TLR10 Polyclonal
goat IgG
Santa Cruz
Biotechnology
1.6 μg/mL Immunohistochemistry II
TNF-? Monoclonal
mouse IgG1
RDI8 0.5 μg/ml Immunohistochemistry III
1) Abcam, Cambridge, UK. 2) Bioss, Woburn, MA, USA.  3)  Cell Signaling Technology Inc.,
Danvers, MA, USA. 4) DAKO,Glostrup, Denmark . 5) Abnova, Taipei city, Taiwan. 6) Santa Cruz
Biotechnology, Santa Cruz, CA, USA. 7) AbD Serotec, Oxford, UK. 8) RDI, Flanders, Belgium.
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4.2.4. TUNEL staining
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining
was completed using the DeadEnd Colorimetric TUNEL System (Promega
Corporation, Fitchburg, WI, USA). Here, 4-μm-thick sections were deparaffinised
and incubated in 20 μg/ml proteinase K solution for 30 min at 37°C, an
equilibration buffer for 10 min at RT, and a rTdT reaction mix for 60 min at 37°C.
The reaction was terminalised by incubating the slides in 2 x SSC for 15 min at RT,
and an endogenous peroxide was blocked by 0.3% H2O2. The slides were
incubated in streptavidin HRP for 30 min at RT, and then the colour was developed
by incubating the slides in DAB substrate for 10 min at RT. The slides were
washed three times for 5 min in PBS after each step.
4.2.5. DNA extraction
We extracted DNA from SCC-25 cells using a DNA extraction kit (Macherey-
Nagel, Düren, Germany). The DNA concentration was measured using the
NanoDrop spectrophotometer ND-1000 (Thermo Fisher Scientific, Wilmington,
DE, USA).
4.2.6. Quantitative real-time PCR (qPCR)
Cells  were  lysed  using  a  RLT  lysis  buffer  and  RNA  was  extracted  using  the
RNeasy  Mini  Kit  (Qiagen,  Düsseldorf,  Germany).  The  total  amount  of  RNA was
measured using the NanoDrop 1000 spectrophotometer (Thermo scientific,
Waltham, MA, USA). cDNA was synthesised by adding an equal amount of total
RNA  to  4  μl  of  reaction  mix  and  1  μl  of  transcriptase  enzyme  to  reach  a  total
volume of 20 μl. The iScript cDNA synthesis kit was used in all studies (Bio-Rad,
Hercules, CA, USA).
To run qPCR, each well in the 96-well plate contained 10-μl iQ SYBR green, 7-μl
water, 1-μl 250 nM primer, and 2-μl cDNA.
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We used two housekeeping genes. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was  used  in  the  first  and  third  studies,  and  ribosomal  protein  large  P0
(RPLP0) was used in the first and fourth studies. Table 8 provides the gene
sequences of the human primers used in this study.
Table 8. Sequence of the human primers used in this study.
Gene Forward Reverse Study
BD-2 5’-ATCAGCCATGAGGGTCTTGT-3’ 5’-GAGACCACAGGTGCCAATTT-3’ IV
GAPDH 5’-AAGGTCATCCCTGAGCTGAA-3’ 5’-TGCTGTAGCCAAATTCGTTG-3’ I, III
IL-17A 5’-CTACAACCGATCCACCTCACCTTG-3’ 5’-GGTAGTCCACGTTCCCATCAGC-3’ III
IL-17C 5’-CGCTGCCGCCACCATGAC-3’ 5’-GCAGTTCCTCAGCCGAGTAGC-3’ III
IL-17RA 5’-CTGGTTCATCACGGGCATCTCC-3’ 5’-GGTGGTCGGCTGAGTAGATGATC-3’ III
IL-17RE 5’-TCCTGGAATGTAAGCATGGATACC-3’ 5’-GGAAGGGAATGATGAGGTCTAGTG-3’ III
IL-6 5’-AGGAGACTTGCCTGGTGAAA-3’ 5’-GAGGTGCCCATGCTACATTT-3’ I
IL-8 5’-TCTGCAGCTCTGTGTGAAGG -3’ 5’-ACTTCTCCACAACCCTCTGC-3’ I, III
RPLP0 5’-GGCGACCTGGAAGTCCAACT-3’ 5’-CCATCAGCACCACAGCCTTC-3’ I, IV
TNF-? 5’-GACAAGCCTGTAGCCCATGT-3’ 5’-TTGATGGCAGAGAGGAGGTT-3’ I, III
4.3. Microscopy and image analysis
Immunostained sections and cells were analysed under a Leica DM6000 B/M light
microscope connected to a digital camera (DFC420 and DFC365FX, Leica
Microsystems, Wetzlar, Germany).
In order to compare the staining intensity between RAU and control samples, the
mean gray values were measured using the Image J program (Wayne Rasband,
National  Institute  of  Mental  Health,  Bethesda,  MD,  USA).  A stop  filter  type  was
used with a hue value between 0 and 161. The relative staining intensity was
determined by applying the inverse mean grey value.
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For the immunofluorescence staining, the corrected total cell fluorescence was
measured to compare the staining intensity between the control and stimulated
cells.
In order to count the number of positive cells in the lamina proparia,  we used the
point counting method from three randomly selected areas under a high-
magnification power field for each slide (400x).
4.4. Statistical analysis
Results are presented as means and standard deviation. The Levene test was used to
check the homogeneity of the variances. In order to compare two groups, Mann–
Whitney U test was used in the first and fourth studies and student T test was used
in the third study. For multiple group comparisons, a one-way ANOVA followed
by  a  Scheffe  post  hoc  test  was  used  in  the  first  study  and  a  one-way  ANOVA
followed by a Fisher’s least significant difference (LSD) post hoc test was used in
the fourth study and. A p value of ≤0.05 was considered statistically significant and
given as * (P ≤ 0.05), **( P ≤ 0.01), ***(P ≤ 0.001), ****(P ≤ 0.0001).
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5. Results
5.1 Expression of the apoptosis marker, danger signals, chemokines, pro-
inflammatory cytokines, antimicrobial peptides, and oxidative stress marker in
healthy and RAU oral mucosa
Apoptosis marker caspase-3
The caspase-3 staining was negative in the control epithelium and lamina proparia
except for a few connective tissue cells undergoing apoptosis during normal tissue
regeneration processes. The RAU epithelium stained strongly positive for caspase-
3 especially in the spinous layer. The caspase-3 positive cells were also more
numerous in the RAU lamina propria (Figure 3). The apoptotic death of oral
epithelial cells in RAU were confirmed by TUNEL staining (data not given).
Danger signal HMGB1
The HMGB1 expression pattern was different between the the control and RAU
epithelium. In the control epithelium, HMGB1 was expressed only in the basal
layer located in the perinuclear area. In RAU, HMGB1 was expressed in all layers
of the epithelium located more in the cytoplasm and the extracellular space. The
HMGB1 positive cells were more numerous in the lamina propria of RAU lesions
compared with the control lamina propria (Figure 3).
IL-17A and IL-17C
Oral epithelial cells were IL-17A negative both in the control and RAU samples
(Figure 3). The inability of oral epithelial cells to synthesise IL-17A was confirmed
by qPCR (Table 9). Some cells in the lamina propria stained strongly positive for
IL-17A. Double immunofluorescence staining of the oral mucosa with IL-17A and
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mast cell tryptase (MCT) proved that mast cells serve as the major producer of IL-
17A in the oral mucosa (Figure 3).
IL-17C  was  weakly  positive  in  control  epithelial  cells.  By  contrast,  in  RAU
epithelial  cells,  it  stained  stained  strongly  positive  (Figure  3).  The  ability  of  oral
epithelial  cells  to  synthesise  IL-17C  was  confirmed  by  qPCR  (Table  9).  The  up-
regulation of IL-17C in RAU epithelial cells was confirmed by measuring the
relative staining intensity, which was significantly higher in RAU epithelial cells
compared with healthy control (p = 0.006; see Table 10).
Inflammatory leukocytes in the lamina propria and oral epithelium were also IL-
17C positive (Figure 3).
Both  IL-17RA  and  IL-17RE  mRNA  were  expreseed  in  the  oral  epithelial  cells
(Table 9).
Table 9. mRNA expression of IL-17A, IL-17C, IL-17RA, and IL-17RE in primary human oral
keratinocytes.
Gene Expression
IL-17A -
IL-17C +
IL-17RA +
IL-17RE +
(-) mRNA was under a detectable level, (+) mRNA was detectable.
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Figure 3. Expression of a select apoptosis marker, a danger signal, and pro-inflammatory cytokines
in control and RAU oral mucosa. Control and RAU oral mucosa were immunostained for caspase-3,
HMGB1, IL-17A, and IL-17C. Double immunofluorescence staining was completed for MCT and
IL-17A: DAPI (blue), IL-17A (red), and MCT (green). Scale bar = 100 μm.
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Chemokine IL-8
While oral epithelial cells in the control samples stained either negative or slightly
positive  for  IL-8,  RAU  epithelial  cells  were  strongly  positive  with  a  staining
pattern similar across all layers of the epithelium and no difference found between
the basal and superficial layers. Some cells in the control and RAU lamina propria
stained positive for IL-8 (Figure 4). The relative staining intensity confirmed the
up-regulation of IL-8 in RAU epithelium compared with healthy control (p = 0.02;
see Table 10).
Pro-inflammatory cytokine TNF-α
The oral epithelial cells in the controls stained slightly positive for TNF-α. By
contrast, the oral epithelial cells in RAU stained strongly positive. This increase
was confirmed by measuring the relative staining intensity (p = 0.04; see Table 10).
The superficial layer was TNF-α negative in both healthy and RAU epithelium.
Only a few cells in the healthy lamina proparia were positive for TNF-α. In RAU,
inflammatory cells infiltrated the lamina proparia and stained positive for both
TNF-α (Figure 4).
Antimicrobial peptides BD-2
We found a significant difference in the expression of BD-2 between healthy and
RAU mucosa. The control epithelium was either BD-2 negative or weakly positive,
with only a few cells in the lamina propria staining positive for BD-2 (Figure 4).
RAU epithelial  cells stained strongly positive for BD-2 and the number of BD-2-
postitive cells in the lamina proparia was significantly higher than that in healthy
mucosa (p = 0.004; see Table 10).
While mast cells and macrophages were identified as the primary producers of BD-
2 in healthy lamina propria, in RAU, BD-2 was primarily produced from infiltrated
inflammatory cells (Figure 5).
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Oxidative stress marker 4-hydroxynonenal (4HNE)
Both healthy and RAU epithelial cells stained positive for 4HNE. In healthy
epithelium, all layers were positive, except for the uppermost layer which was
negative. In RAU, staining was stronger, but did not reach statistical significance (p
> 0.05; see Table 10). In contrast to healthy epithelium, the uppermost layer stained
intensely positive for 4HNE, and even stronger than other layers of the RAU
epithelium (Figure 4).
Table 10. Staining intensity of select antigens in control and RAU oral epithelium.
Antigen Staining intensity
Control                                          RAU
p values
IL-17C 0.3 ± 0.09 1.0 ± 0.6 p = 0.006
IL-8 0.8 ± 0.06 1.0 ± 0.2 p = 0.02
TNF-? 0.1 ± 0.1 1.0 ± 1.0 p = 0.04
BD-2 1.0 ± 0.2 5.0 ± 6.5 p = 0.001
4HNE 1.0 ± 1.0 2.2 ± 1.6 p > 0.05
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Figure 4. Expression of select chemokine, pro-inflammatory cytokine, antimicrobial peptide, and
oxidative  stress  markers  in  healthy  and  RAU  oral  mucosa.  Healthy  and  RAU  oral  mucosa  were
immunostained for IL-8, TNF-α, BD-2, and 4HNE. Scale bar = 100μm.
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Figure 5. Identification of BD-2-producing cells in healthy and RAU oral mucosa. Healthy and
RAU oral mucosa were subjected to immunofluorescence staining for BD-2, MCT, and CD68.
Healthy oral mucosa (A & C); RAU mucosa (B & D). BD-2 and MCT (top row); BD-2 and CD68
(bottom row). DAPI (blue), BD-2 (red), MCT (green), CD68 (green), and co-localisation of BD-2
with MCT or CD68 (yellow). Scale bar = 50 μm.
5.2. TLR expression pattern in RAU lesions and healthy control mucosa
TLR expression was studied in the biopsy samples taken from the  healthy controls,
ulcerated RAUs, and two samples taken from the healthy mucosa of RAU patients.
The  pattern  of  TLR  distribution  is  clearly  different  in  RAU  lesions  compared  to
that from the control samples (Figure 6).
In the control oral epithelium, most TLRs share the same pattern of expression,
being strongly positive at the basal and suprabasal layers of the epithelium. TLR
expression decreased towards the superficial layer of the epithelium where it first
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disappeared in the middle layer for all TLRs except TLR7, while the superficial
layer showed a slight staining for TLRs.
In RAUs, the pattern of expression clearly differed. The basal and suprabasal layers
stained most intensively positive for TLRs, but the pattern differed in the other
layers (lower, middle, and upper spinal layers) since these layers stained positive
for TLRs in RAU.
While most TLRs were quite similar in their pattern of expression in both the
control and RAU epithelium, some showed differences since TLR7 expressed in all
layers  of  healthy  epithelium,  yet  remained  more  strongly  positive  in  RAU.  TLR9
was negative in almost all layers for both the control and RAU epithelium.
The two healthy samples taken from RAU patients did not differ from the healthy
control mucosa (data not shown).
In the lamina propria, the connective tissue cells (endothelial cells, fibroblasts, and
leukocytes) stained positive for all TLRs except for TLR9 (data not shown).
Despite the positive stains for most connective tissue cells in both healthy and
RAU  lesions,  the  number  of  cells  was  higher  in  RAU  compared  to  that  in  the
healthy controls resulting from leukocyte migration towards the inflamed area.
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Figure 6. TLR expression in healthy and RAU oral mucosa. Healthy control (HC) and RAU
oral mucosa were immunostained for TLR1-10. TLR expression in the epithelium of healthy
control and RAU were graded as follows: 0 = negative; 1 = weakly positive; 2 = moderately
positive; 3 = strongly positive.
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5.3. Functional studies of cultured primary oral keratinocytes, oral keratinocyte
SCC-25 cell lines, and primary gingival fibrobasts
Effect of TNF-α and IFN-γ on TLR2 and TLR4 mRNA
We studied the effect of pro-inflammatory cytokines on the expression of TLRs in
vitro. TNF-α and IFN-γ were selected based on their effect on TLR expression in
other cell types. TLR2 and TLR4 were selected as the target receptors since they
possess the ability to bind with both PAMPs (as LPS) and DAMPs (as HMGB1).
Neither TNF-α nor IFN-γ alone was able to increase TLR2 mRNA. By contrast, the
synergistic effect of TNF-α and IFN-γ significantly up-regulated TLR2 mRNA (p =
0.01; Figure 7A). This increase was also shown at the protein level by
immunofluorescence staining (Figures 7B–C).
We found a different situation with TLR4. TNF-α did not increase TLR4 mRNA,
but IFN-γ alone led to a noticeable increase in the TLR4 mRNA even though it did
not reach statistical significance due to a high skewed deviation. Adding TNF-α to
IFN-γ did not yield an additional effect on the TLR4 mRNA (p > 0.05; Figure 7C).
While TNF-α and IFN-γ did not significantly affect mRNA expression, their effect
on the protein level was clear (Figure 7E–F).
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Figure 7. TLR2 and TLR4 expression in controls and TNF-α and IFN-γ stimulated human oral
keratinocyte SCC-25 cells. Human oral keratinocyte SCC-25 cell lines were stimulated with 50
ng/ml TNF-α, 50 ng/ml IFN-γ, and both combined for 4 and 24 h, respectively. TLR2 (A) and
TLR4 (D) mRNA were measured using qPCR. The TLR2 (B–C) and TLR4 (E–F) protein levels
were shown using immunofluorescence staining; control SCC-25 cells (B, E); TNF-α and IFN-γ
stimulated SCC-25 cells (C, F). DAPI (blue); TLR2 and TLR4 (red). Scale bar = 50 μm.
Loss of nuclear HMGB1 from SCC-25 after activation with TNF-α
Human oral keratinocytes SCC-25 were cultured on coverslips and stimulated with
50  ng/ml  TNF-α for  24  h.  In  control  cells,  HMGB1  was  found  in  the  nucleus
(Figure 8A). Most of the stimulated cells lost their HMGB1 and their nuclei were
HMGB1 negative or weakly positive (Figure 8B). The corrected total cell
fluorescence for the control SCC-25 cells was significantly higher than that in the
stimulated cells (p ≤ 0.0001, data not given).
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Figure 8. HMGB1 expression in healthy control and TNF-α stimulated human oral keratinocyte
SCC-25 cells. Human oral keratinocyte SCC-25 were cultured on coverslips and stimulated with 50
ng/ml TNF-α for 24 h. Cells were subjected to immunofluorescence staining with HMGB1. Non-
stimulated cells (A); stimulated cells (B). DAPI (blue); HMGB1 (red). Scale bar = 100 μm.
Stimulation of SCC-25 cells and fibroblasts with different forms of HMGB1
Here, 1000 ng/ml all-thiol HMGB1, 1000 ng/ml disulfide-HMGB1, 50 ng/ml IFN-
γ, or a combination of disulfide-HMGB1 and IFN-γ were used to stimulate SCC-25
cells for 8 and 24 h. None of the stimulants, neither alone nor in combination with
each other, up-regulated IL-8, IL-6, or TNF-α mRNA (data not given).
Gingival fibroblasts, another oral mucosal cell type, were tested in the HMGB1
functional  assay.  Similar  to  the  results  from  SCC-25  cells,  none  of  the  HMGB1
forms up-regulated IL-8, IL-6, or TNF-α mRNA (data not given).
In  order  to  check  the  functionality  of  TLR4,  a  low  dose  of  LPS  (10  ng/ml)  was
used to stimulate gingival fibroblasts alone or in combination with disulfide-
HMGB1. Even with such a low concentration, LPS was able to up-regulate IL-8 (p
≤ 0.0001) and IL-6 (p ≤ 0.001), but not TNF-α. The combination of disulfide-
HMGB1 with LPS did not yield an additional up-regulation compared to LPS alone
(Figure 9).
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Figure 9. Effect of LPS and disulphide-HMGB1 (DS-HMGB1) on the expression of IL-8, IL-6, and
TNF-α in human gingival fibroblasts. Gingival fibroblasts were stimulated with 1000 ng/ml DS-
HMGB1, 10 ng/ml LPS, and both for 24 h. IL-8 (A), IL-6 (B), and TNF-α (C) mRNA were
measured using qPCR.
Stimulation of SCC-25 cells with self-DNA
SCC-25 cells were stimulated using 50 ng/ml self-DNA extracted from SCC-25
cells for 8 and 24 h. While IL-8 mRNA was not affected by self-DNA (Figure
10A), TNF-α mRNA was significantly up-regulated after 24 h of stimulation (p =
0.02; Figure 10B).
Figure 10. Effect of self-DNA on the expression of IL-8 and TNF-α in human oral keratinocyte
SCC-25 cells. Human oral keratinocyte SCC-25 cells were stimulated with 50 ng/ml self-DNA for 8
and 24 h. IL-8 (A) and TNF-α (B) mRNA were measured using qPCR.
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Effects of IL-17C on human primary oral keratinocytes
Human oral keratinocytes were stimulated using 100 ng/ml IL-17C for 4 and 12 h.
After the first 4 h, we found a slight increase in the IL-8 and TNF-α mRNA from
the stimulated cells compared with the control cells, but the difference was not
statistically significant. After 12 h, IL-17C significantly up-regulated TNF-α
mRNA (p = 0.03). We found a similar increase in the IL-8 mRNA, but the
difference was not statistically significant (p > 0.05; Figure 11).
Figure 11. Effect of IL-17C on the expression of IL-18 and TNF-α in primary human oral
keratinocytes. Human primary oral keratinocytes were stimulated with 100 ng/ml IL-17C for 4 and
12 h. IL-8 (A) and TNF-α (B) mRNA were measured using qPCR.
Synergistic effect of TNF-α and IL-17C in the presence or absence of oxidative
stress on the production of BD-2 from SCC-25 cells
SCC-25 cells were stimulated using 100 ng/ml IL-17C, 10 ng/ml TNF-α, or both
together. While IL-17C did not affect BD-2 mRNA, TNF-α significantly up-
regulated BD-2 mRNA (p < 0.0001). This up-regulation increased further when IL-
17C was added together with TNF-α (p < 0.0001). The BD-2 mRNA level was
significantly higher in TNF-α and IL-17C stimulated cells than when using TNF-α
alone (p = 0.02; Figure 12A).
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Oxidative stress was induced in the cultured cells by adding vitamin K3. Vitamin
K3 did not affect the BD-2 mRNA neither in the ‘unstimulated’ control cells nor in
the ‘TNF-α and IL-17C stimulated’ activated cells (Figure 12B).
Figure 12. Effect of TNF-α and IL-17C on the expression of BD-2 in healthy control and stressed
human oral keratinocyte SCC-25 cells. Human oral keratinocyte SCC-25 cells were stimulated with
100 ng/ml IL-17C, 10 ng/ml TNF-α, and both in the absence (A) and presence of vitamin (vit) K3
for 24 h. BD-2 mRNA was measured using qPCR.
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Table 11. Summary of mRNA and protein expression of the molecules studied in the oral
epithelium of control and RAU samples and cultured primary oral keratinocytes, squamous cell
carcinoma SCC-25, and primary gingival fibroblasts.
Molecule Tissue sample Cultured cells Study
Control RAU HOK SCC-25 Gingival fibroblast
Protein Protein mRNA Protein mRNA Protein mRNA Protein
4HNE + + IV
BD-2 -/+ + + IV
Caspase-3 - + I
HMGB1 + + + I
IL-6 + + I
IL-8 + + + + + I, III
IL-17A - - - III
IL-17C + + + III
IL-17RA + III
IL-17RC + III
TLR1 + + II
TLR2 + + + + I, II
TLR3 + + II
TLR4 + + + + I, II
TLR5 + + II
TLR6 + + II
TLR7 + + II
TLR8 + + II
TLR9 + + II
TLR10 + + II
TNF-? + + + + + I, III
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6. Discussion
6.1. Epithelial cell death in RAU: apoptosis or necrosis?
Ulceration may be defined as the full thickness loss of epithelium (Sonis, 2007).
This loss can be caused either by the sloughing of the epithelium resulting from
trauma such as a traumatic ulcer or by epithelial cell death caused by necrosis or
apoptosis. In earlier studies of RAU, the mechanism for oral epithelial cell death
received relatively little attention. In our research on the role of apoptosis in RAU,
we only found one study claiming that apoptosis plays a role in RAU. In that study,
an electron microscope was used to identify the features of apoptosis in epithelial
cells including nuclear and cytoplasmic shrinkage (Honma et al., 1985).
In our study, we used cleaved caspase-3 and TUNEL staining to show apoptotic
cells  in  RAU.  Our  results  agreed  with  previous  studies  on  apoptosis.  The  oral
epithelial cells stained strongly positively in RAU lesions and completely
negatively in healthy controls. The pattern of caspase-3 expression was not the
same through all layers of the RAU epithelium since it was weak in the basal layer,
very strong in the middle layer, and strong in the superficial layer. Such an
expression may indicate that the epithelial cell death begins from the superficial
layer resulting from a strong and sudden triggering factor, decreasing down to the
basal layer.
Caspase-3 was not expressed in the control epithelium, agreeing with proven
phenomena. This suggests that in healthy oral mucosa oral epithelial cells flow
from the deep layer to the superfacial layer where they detach from the undelying
layer of the oral epithelium. They then undergo apoptosis as a result of the loss of
cell–cell contact (Loro et al., 2005).
Our results were unexpected, since apoptosis is not normally accompanied by
inflammation given that all cellular contents and DAMPs are preserved inside
apoptotic bodies, and then cleared by macrophages, contrary to what we find in
RAU where the ulcer is surrounded by an inflamed halo area (Natah et al., 2004).
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This discrepancy may be explained by one of two theories: secondary necrosis and
necroptosis. The first theory, secondary necrosis, depends on whether apoptotic
bodies remain in the tissue for a long time, when they enter secondary necrosis
with features similar to necrosis. While macrophages are quite efficient in
engulfing cellular debris, this efficiency may not be suffiicent to handle the huge
number of apoptotic keratinocytes which result from massive transepithelial
apoptosis. As a result of this delay in the elimination of apoptotic bodies, they may
result  in  secondary  necrosis  and  the  release  of  DAMPs,  such  as  self-DNA  and
HMGB1 (Abdulahad et al., 2010). The role of secondary necrosis and the release of
alarmins were found in other epidermal diseases, such as lupus erythematosus.
Here, ultraviolet radiation was found to trigger lupus, activating apoptosis cascades
in keratinocytes, potentially leading to huge numbers of apoptotic keratinocytes.
Macrophages failed to deal with all apoptotic bodies, potentially leading to
secondary necrosis and the release of HMGB1 (Abdulahad et al., 2010; Baumann
et al., 2002).
The second theory suggests a new mechanism of cell death which includes
necroptosis or programmed necrosis and is also associated with inflammation. On
the one hand, the necroptosis theory may be applied to RAU since necroptosis may
be initiated after the activation of TLRs as TLR3 and TLR4 or by TNF-α,  where
both  TLRs  and  TNF-α are  overexpressed  in  RAU  (Shalini  et  al.,  2015).  On  the
other hand, the biggest drawback of this hypothesis in this context is that it is
associated with the inactivation of caspase-3, which is activated in RAU epithelium
(Gunther et al., 2011; Han et al., 2015; Li et al., 2011). Further studies on other
markers of necroptosis in RAU are needed.
6.2. HMGB1: an increase in the expression in RAU but has no clear function
HMGB1 is regarded as one of the most important DAMPs (Wang et al., 1999). In
healthy oral epithelium, HMGB1 is found in the perinuclear area of the oral
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epithelial cells in the basal layer, which is the only active layer and the only layer
which allows for mitosis. The expression of HMGB1 in this layer is understandable
since HMGB1 is known to play an important role during cell mitosis through
transcription, replication, and cellular differentiation (Stros, 2010). The other layers
of oral epithelium were HMGB1 negative. Since all cells have a specific amount of
HMGB1, then the possible explanation for this negative staining of HMGB1 relies
on it being tightly bound inside the nucleus. This results from its lack of function in
these cells due to the loss of its ability in cell division, rendering it unrecognisable
to the antibody (Heinola et al., 2010).
In RAU, HMGB1 was found in all layers of the epithelium. It was expressed more
in  the  cytoplasm  and  extracellularly.  This  dramatic  change  in  the  expression  of
HMGB1 in the oral epithelium may be explained either by its undergoing apoptosis
since HMGB1 is known to first translocate to cytoplasm and then to extracellular
tissue during apoptosis (Abdulahad et al., 2010; McNamara et al., 2010). This may
also result from the activation of oral epithelial cells stimulating SCC-25 using
TNF-α leading  to  a  loss  of  HMGB1  from  the  nuclei.  A  similar  expression  of
HMGB1 was found in murine-injured skin compared with a healthy control
(Straino et al., 2008).
Our results showing the presence of  HMGB1 expression  in all epithelial layers of
RAU lesion is of  importance as TLR4, the receptor for HMGB1 (Venereau et al.,
2012), has the same pattern of expression in RAU. This indicates that   these cells
have the ability both  to release HMGB1 and also to respond to it.
HMGB1 plays an important role in inflammation through stimulating macrophages
to produce chemokines and pro-inflammatory cytokines (Venereau et al., 2012).
However, very little is known about the effects of HMGB1 on oral epithelial cells,
especially in terms of the production of chemokines and pro-inflammatory
cytokines.  Therefore,  we  studied  the  effect  of  different  forms of  HMGB1 on  oral
epithelial cells. Contrary to our expectations, none of these forms increased the
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mRNA  of  IL-8,  IL-6,  and  TNF-α.  Next,  we  added  IFN-γ to  the  medium  with
disulfide-HMGB1,  since  previous  studies  showed  that  LPS  shares  the  same
receptors, TLR2 and TLR4, and requires IFN-γ to stimulate oral epithelial cells
(Uehara et al., 2002). Even with IFN- γ, HMGB1 did not affect the oral epithelial
cells.
In the next step,  we chose gingival fibroblast,  another type of cell  present in oral
mucosa, which may also play a role in aggravating inflammations in RAU lesions.
Similar  results  were  obtained  forfibroblasts  and  oral  epithelial  cells.  Then,  we
checked the functionality of TLR4 by stimulating fibroblasts using a low
concentration of LPS. Using a concentration of 10 ng/ml,  which is 100 times less
than the concentration used for HMGB1, LPS increased IL-8 and IL-6 mRNA,
suggesting that the problem of HMGB1 stimulation was unrelated to its receptor,
but attributed to the protein itself.
Since this is the first report regarding the inability of HMGB1 to affect oral
keratinocytes in terms of the production of chemokines and pro-inflammatory
cytokines, we recommend carrying out further experiments in future using another
cell line and attempting to find a synergistic effect between HMGB1 and other
proteins. If further experiments yield negative results that support ours, then it may
be that HMGB1 stimulates inflammatory cells such as macrophages, but not other
non-professional immune cells such as keratinocytes.
6.3. Self-DNA: another alarmin in RAU
During secondary necrosis, several molecules are passively released from
secondary necrotic cells to the extracellular space (Abdulahad et al., 2013). First,
we discussed HMGB1 as an example of proteins which work as an alarmin. Here,
we took self-DNA as another example for DAMPs. Self-DNA was extracted from
oral keratinocytes and used to stimulate the same cells in order to simulate necrosis
in vivo. Oral keratinocytes were stimulated with self-DNA without needing a
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transfecting agent since keratinocytes carry the ability to take up DNA using
macropinocytosis (Basner-Tschakarjan et al., 2004). While we are unsure which
receptor is responsible for binding to self-DNA, the effect of this binding was quite
clear through the up-regulation of TNF-α mRNA. IL-8 mRNA was not affected by
self-DNA, demonstrating the specificity of this stimulation.
The ability of oral keratinocytes to respond to their own DNA stimulation may
partially support our hypothesis about identifying oral epithelial cells as
inflammatory cells in RAU. These cells may play a significant role in inducing
inflammation in the inflammatory halo area around the ulcer edge by secreting
intracellularly confined danger signals which work as as alarmins in pathological
conditions such as RAU. These alarmins may stimulate adjacent epithelial cells at
the ulcer margins to produce pro-inflammatory cytokines and exacerbate the
inflammation.
6.4. TLR up-regulation in RAU
Oral epithelium is the first  line of defence in the oral  mucosa.  Due to its  physical
characteristics, it provides physical protection against microbial invasion, irritation,
and trauma (Beklen et al., 2008). In addition, oral epithelial cells are equipped with
10 TLRs, which have the ability to recognise microbes through their  PAMPs (Ali
et al., 2008). Such recognition leads to the immediate production of chemokines,
pro-inflammatory cytokines, and antimicrobial peptides. Rapid reaction provides
immediate defence against the microbes before the arrival of inflammatory cells. In
healthy oral epithelium, TLR receptors were found only in the basal and suprabasal
layers. This distribution provides protection against the continuous activation of
TLRs, since the superficial layer of oral epithelium is in direct contact with
commensal oral microbes, which share some PAMPs with pathogenic microbes. As
a  result  of  this  distribution,  only  microbes  with  the  ability  to  invade  into  the
suprabasal and basal layers of epithelium can activate TLRs.
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TLRs are  distributed  through all  layers  of  oral  epithelium in  RAU (including  the
superficial layer) in contrast to healthy epithelium. As a result of this distribution,
TLRs are activated by penetrating microbes throughout the ulcer area. The ulcer
area  provides  easy  access  to  microbes,  as  well  as  to  commensal  and  pathogenic
microbes in the oral cavity which have direct contact with the superficial layer of
the oral epithelium. The chemokines produced from activated epithelial cells lead
to the recruitment of inflammatory cells, which also have TLRs. Such cells form a
third line of defence (Uehara et al., 2002).
The distribution of TLRs in non-ulcerated RAU epithelium mimicked healthy
epithelium, indicating that this up-regulation of TLRs is not a constant feature, but
a part of the inflammatory process associated with RAUs. Differences in the TLR
distribution between a RAU lesion, periodontitis, and candidiasis show that this
distribution is affected by the type of inflammation (chronic or acute), the type of
cytokines produced in the area, and the type of PAMPs and DAMPs associated
with the lesion (Ali et al., 2008; Beklen et al., 2008).
Several cytokines, such as transforming growth factor (TGF)-α, TNF-α, IFN-γ, IL-
1β,  and  G-CSF,  and  PAMPs  such  as  poly  (I:C),  LPS,  LTA,  and  soybean
lipoxygenase (SLO), may up-regulate TLRs as TLR1, TLR2, TLR3, TLR5, and
TLR9 in different types of cells, including endothelial cells, small airway epithelial
cells, and skin keratinocytes (Joo et al., 2011; Lew et al., 2009; Miller et al., 2005;
Ritter et al., 2005; Satta et al., 2008).
In this project, we selected two cytokines expressed in RAU mucosa and tested
their effect on TLR2 and TLR4 (Al-Samadi et al., 2014; Buno et al., 1998). TLR2
and TLR4 carry the ability to bind with both PAMPs (e.g., LPS) and DAMPs (e.g.,
HMGB1). Our results clearly showed that neither TNF-α nor IFN-γ alone had an
effect on TLR2 expression. However, when SCC-25 cells were exposed subjected
to both simultaneously, the TLR2 expression was significantly up-regulated,
pointing to the importance of cell priming with IFN-γ in oral keratinocyte SCC-25
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cells. TLR4 mRNA behaves differently since IFN-γ alone was sufficient to achieve
a noticeable increase in TLR4 mRNA although not statistically significant. We also
found no synergistic effect between TNF-α and IFN-γ. Our results partially agreed
with Uehara et al., who claimed that IFN-γ alone up-regulates TLR4 (Uehara et al.,
2002). At the same time, our results contradict those of Uehara et al. who showed
that IFN-γ alone up-regulates TLR2 (Uehara et al., 2002). Such a discrepancy may
stem from the fact that they stimulated the oral epithelial cells for three days in
their experiment, which is a relatively long time, during which oral keratinocytes
may produce TNF-α. Previous studies found that these cells include the ability to
continuously produce TNF-α in a cell culture media (Formanek et al., 1999). The
accumulation of TNF-α in the medium may act in a synergistic manner with IFN-γ.
To  overcome  this  problem,  we  stimulated  cells  for  only  4  h.  Even  with  such  a
short-duration stimulation, TLR2 was significantly up-regulated and TLR4 was
noticeably up-regulated. Such a quick up-regulation may provide an indication of
how fast the inflammatory process may be initiated in RAU. These results were
also supported by the increase in the TLR2 and TLR4 protein levels in TNF-α and
IFN-γ stimulated SCC-25 cells as detected by immunofluorescence staining.
6.5. IL-17C: an active player in RAU
IL-17C  is  a  relatively  new  member  of  the  IL-17  family.  It  shares  some
characteristics with other IL-17 family members even though it is not produced by
Th17 cells  (Iwakura  et  al.,  2011).  Since  we concentrated  here  on  the  role  of  oral
epithelial cells in RAU, we took IL-17C as a suitable example of pro-inflammatory
cytokines.  Our  selection  was  dependent  on  the  fact  that  epithelial  cells  are  the
primary producers of IL-17C. Previous findings showed that epithelial cells may be
activated by TLR ligands to produce IL-17C (Ramirez-Carrozzi et al., 2011). The
regulation of IL-17C by TLRs is important in RAU lesions, as we demonstated
with TLRs up-regulation and exposure to a variety of PAMPs and DAMPs.
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Our qPCR results proved that oral  epithelial  cells carry the ability to produce IL-
17C, but not IL-17A. These cells were also IL-17RA and IL-17RE mRNA positive,
meaning that they are not just major producers of IL-17C, but that they can respond
to it.
Immunostaining of oral mucosa from healthy controls and RAU lesions confirmed
our results of qPCR since IL-17C was weakly positive in healthy epithelium and
strongly positive in RAU. Our first explanation regarding the presence of IL-17C in
healthy epithelium stems from the tissue being taken from oral mucosa during
wisdom tooth extraction. Furthermore, this mucosa may have subclinical
inflammation even though we selected these samples to be clinically and
histologically healthy. Our conclusions have shifted, however, after Johnston et al.
reported the positive staining of IL-17C in healthy skin keratinocytes (Johnston et
al., 2013). The presence of IL-17C in healthy oral epithelium may provide baseline
protection against harmful conditions. Given these results, we argue that studies on
the role of IL-17C in keratinocyte proliferation and specifically the balance
between epithelial cell apoptosis and proliferation are required.
In  RAU,  the  expression  of  IL-17C  in  oral  epithelial  cells  increased  significantly.
Such an increase is not surprising given that TLRs are up-regulated and expressed
in all layers of the epithelium, making the cells more responsive to stimulants.
Additionally, the oral cavity is not a sterile field and is full of several PAMPs.
The overexpression of IL-17C may induce a severe and self-amplifying
inflammatory cycle as we demonstrated here. IL-17C increased the production of
TNF-α significantly and TNF-α is known as an inducible agent for IL-17C
(Johansen et al., 2011). Our cell culture results were supported by the results from
clinical lesions of RAU patients given that the immunostaining of healthy and
RAU oral mucosa revealed a significant increase in TNF-α in the oral epithelium of
RAU  when  compared  with  healthy  controls.  In  addition  to  oral  epithelial  cells,
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neutrophils highly infiltrated in both epithelium and lamina proparia to provide a
second source of IL-17C.
We studied IL-17A here as a negative control. Oral epithelial cells were IL-17A
negative in both the control and RAU lesions. Some cells in the lamina proparia
stained positive, forming an internal positive control, in both the control and RAU
lesions. Based on the morphology of the cells, we hypothesised that these cells are
mast cells. Double immunofluorescence staining of MCT and IL-17A confirmed
our  hypothesis.  This  also  supports  our  assumption  that  mast  cells  represent  the
primary producers of IL-17A in oral mucosa. Similar results have also been
reported for psoriasis, rheumatoid arthritis, and esophageal squamous cell
carcinoma (Kouri et al., 2014; Lin et al., 2011; Wang et al., 2013).
6.6. Oxidative stress in RAU
Oxidative stress has been studied intensively as a possible cause for RAU. All of
these studies investigated the total oxidant/antioxidant status in the plasma and
saliva of RAU patients comparing them with healthy controls. Here, we studied the
oxidative stress in oral epithelium for the first time. Indeed, 4HNE, an endproduct
of lipid peroxidation, was expressed in both the control and RAU samples, but with
no clear difference. Our results prove interesting given that the superficial layer of
the oral epithelium was strongly positive for 4HNE compared with the control
which was negative. Such an expression may suggest that oxidative stress begins in
the superficial layer as a result of a strong initiating stimulus moving into the
deeper layers. This suggestion is also supported by the expression of caspase-3,
which expresses strongly at the superficial and middle layer and quite weakly at the
basal layer.
To test if the oxidative stress affects the mucosal immune defence, we induced
oxidative stress in a cell culture by adding vitamin K3 to the SCC-25 cell culture
medium. Stressed and non-stressed SCC-25 cells behaved similarly in term of BD-
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2 expression. These results indicate that oxidative stress has no significant effect on
the defence mechanism of oral epithelial cells, which may also explain the strong
expression of BD-2 in RAU.
6.7. Protection of the ulcer area by BD-2
As mentioned before, the oral mucosa of RAU lesions subjected to several types of
microbes have direct access to the area through the ulcer. The PAMP–TLR
interaction may initiate a self-amplificatory cycle in RAUs. Since RAU is a self-
healing ulcer taking up to 14 days to heal spontaneously, this suggests that the
cycle may be interrupted somewhere (Belenguer-Guallar et al., 2014), which may
serve as the first step in the healing process.
The rapid healing of an acute inflammation such as RAU may indicate that oral
mucosa carries a strong defence mechanism against microbial invasion.
Antimicrobial peptides are known to be very efficient microbicidal agents which
work similarly to some synthetic antibiotics. Between these peptides, beta
defensins represent the most important peptides in the oral epithelium. Beta
defensins are divided into two types: non-inducible (continuous release) beta
defensins such as BD-1 which express even in healthy epithelium and provide
continuous protection to oral mucosa, and inducible beta defensin such as BD-2
and BD-3 (Gursoy and Kononen, 2012).
As a result of an acute inflammation in and around the ulcer area, finding a high
expression of both the oral epithelium and inflammatory cells infiltrating the
lamina proparia of a RAU lesion is unsurprising.
BD-2 may be induced by several cytokines and PAMPs (Kanda et al., 2011). In
RAU, the reason for the increase in BD-2 production remains poorly understood. In
our study, we selected two cytokines, TNF-α and IL-17C, which we already found
up-regulated in RAU epithelium. In contrast to epidermal keratinocytes in which
IL-17C stimulates keratinocytes to produce BD-2 (Ramirez-Carrozzi et al., 2011),
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BD-2 mRNA expression did not increase after exposing the oral keratinocyte cell
line to IL-17C. Our experiments demonstrated the important role of TNF-α in the
immune  defence  of  the  epithelium  given  that  TNF-α increased  the  BD-2  mRNA
more than 100-fold. Since it is already known that IL-17A can work with TNF-α in
a synergistic manner (Moniaga et al., 2011; Simanski et al., 2013), we tested this
for IL-17C. BD-2 mRNA expression increased significantly after simultaneous
stimulation  with  TNF-α and  IL-17C  as  compared  with  TNF-α only.  The  similar
synergistic behavior of IL-17A and IL-17C  with TNF-α may be explained by the
signaling pathways of these two cytokines.
BD-2 positive cells in the lamina proparia of RAU lesions were significantly higher
than in healthy control cells. This increase resulted from the migration of
inflammatory cells to the inflamed area. In healthy lamina proparia, macrophages
and mast cells, which are always present in oral mucosa, were identified as the
primary  source  of  BD-2.  In  RAU,  the  situation  differs  due  to  the  arrival  of
inflammatory cells which are BD-2-positive cells.
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7. Conclusions
This study focused on the behavior of oral epithelial cells in RAU lesions,
especially  in  terms  of  oral  epithelial  cell  death,  TLR  expression,  the  response  of
oral epithelial cells to pro-inflammatory cytokines and DAMPs, and the production
of chemokines, pro-inflammatory cytokines, and antimicrobial peptides. Our main
findings are as follows:
A. Oral epithelial cells in RAU stained positive for apoptosis markers caspase-
3 and TUNEL. These results indicate that the death of oral epithelial cell
begins with a strong triggering factor inducing apoptosis. In turn,
transepithelial oral epithelial cell apoptosis leads to the sloughing of the oral
epithelium and ulcer formation. The association of inflammation with the
apoptotic death of the oral epithelial cells in RAU may be returned to
secondary necrosis or necroptosis.
B. TLRs  are  up-regulated  in  RAU  lesions  and  expressed  in  all  layers  of  the
epithelium, contrary to healthy controls where they are expressed only in
the basal and supra basal layers of the epithelium. This up-regulation may
increase  the  response  of  oral  epithelial  cells  to  PAMPs and  DAMPs.  TLR
up-regulation may be a result of the underlying inflammation since
inflammatory  cytokines  (TNF-α and  IFNγ)  were  able  to  increase  the
expression of TLR2 in SCC-25 cells.
C. DAMPs (such as self-DNA) and pro-inflammatory cytokines (such as IL-
17C) were able to stimulate oral epithelial cells to produce TNF-α. IL-8,
TNF-α,  and  IL-17C  were  strongly  expressed  in  RAU  oral  epithelium  and
were significantly higher in RAU epithelium compared with the control
epithelium. The activation of oral epithelial cells and the secretion of TNF-
α point to the ability of these cells to behave like pro-inflammatory cells in
RAU.
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D. The antimicrobial peptide BD-2 is strongly expressed in RAU epithelium
and its expression is significantly higher in RAU epithelium compared with
healthy controls. Such an increase in this expression level may result from
the synergistic effect between TNF-α and IL-17C.
As a final conclusion based on our results, we argue that the onset of RAU may be
precipitated by a strong triggering factor inducing apoptosis and ulcer formation in
the oral epithelium. DAMPs are released from dying cells and up-regulate
inflammation through stimulation of the oral epithelial cells to produce chemokines
and pro-inflammatory cytokines. Pro-inflammatory cytokines first up-regulate
TLRs in the oral epithelium making cells more responsive to PAMPs and DAMPs.
Second, they stimulate oral epithelial cells to produce antimicrobial peptides to kill
microbes and initate the healing process.
Due to the lack of memory, a new trigger leads to recurrence and, under each cycle,
the same sequence of events occurs. This RAU cycle is illustrated in Figure 13.
Figure 13. Illustration of the RAU cycle.
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